Preprint
Article

This version is not peer-reviewed.

Integrative Network Meta-Analysis Reveals Estrogen-Mediated RUNX2–PDLIM3–microRNA Crosstalk via Erg Signaling: Implications for Bone and Tissue Regeneration

Submitted:

16 November 2025

Posted:

18 November 2025

Read the latest preprint version here

Abstract

Estrogens govern the female reproductive cycle indefinitely. Estrogens, including estrone (E1), estradiol (E2), estriol (E3), and estetrol (E4), regulate the female life cycle since early embryonic stages and play a crucial role in development, metabolism, and cell function. Throughout evolution, estrogen has regulated reproduction by affecting reproductive organ development and behavior. Estrogen impacts all vertebrates, including fish, and has a role in physiological and pathological states in both genders. The RUNX-2 gene is a member of the RUNX family of transcription factors and encodes a nuclear protein with a Runt DNA-binding domain. This protein is essential for osteoblastic differentiation and skeletal morphogenesis and acts as a scaffold for nucleic acids and regulatory factors involved in skeletal gene expression. The protein can bind DNA both as a monomer or, with more affinity, as a subunit of a heterodimeric complex. In 2022, a study was conducted to characterize novel genes that are regulated by estrogen binding to its receptors (α or β). The PDLIM3 gene, with a coefficient of variation (CV) of 0.083, received the most stable CV score among other genes. Our integrative research uncovers a unique regulatory cascade in which estrogen binding to ERα/β enhances PDLIM3 expression, then modulating the expression of miR-9, miR-10, and the newly identified miR-6769b, finally activating RUNX2 transcription.

Keywords: 
;  ;  ;  ;  ;  ;  ;  ;  

I. Introduction

Estrogen, a steroid hormone playing a fundamental role in the female reproductive tract, is an essential regulator of reproductive physiology. Besides its traditional roles, estrogen possesses neuroprotective activity in preventing neurodegenerative disorders such as dementia and reducing the severity of traumatic brain injury. It is also widely utilized in hormone replacement therapy (HRT) for the treatment of symptoms of menstrual irregularities and menopause [1,2]. Among all of the endogenous estrogens, 17β-estradiol (E2) is the most potent and biologically active form found in systemic circulation. E2 regulates a wide array of physiological events in diverse tissues and organs by diffusing through the plasma membrane of target cells and binding to intracellular estrogen receptors (ERs), i.e., ERα and ERβ [2,3]. These bindings trigger cascades of signals that can be divided into genomic and non-genomic mechanisms. In genomic mechanisms, the estradiol-ER complex undergoes a hormone-binding conformational change, translocates into the nucleus, and binds to estrogen response elements (EREs) in enhancer regions, promoters, or untranslated regions of estrogen-responsive genes [4,5]. This receptor-DNA interaction controls gene transcription and subsequent protein synthesis. Otherwise, estrogen may act with membrane-bound receptors such as GPER1 or cytoplasmic ERs in non-genomic signaling, triggering rapid activation of intracellular signaling cascades independent of genomic interaction [6,7]. Both modes of action point to the sophistication and flexibility of the hormone's function in human physiology. The complex moves to the nucleus and attaches to chromatin at ERE sequences, enhancer regions near promoters, and 30-untranslated regions of target genes. (Figure 1). The RUNX2 gene in humans encodes the transcription factor known as Runt-related transcription factor 2 (RUNX2) or core-binding factor subunit alpha-1 (CBFα1). RUNX2 is recognized as an early marker of osteogenic differentiation and plays a pivotal role in initiating osteoblast-specific extracellular matrix (ECM) synthesis by regulating the expression of critical matrix proteins such as collagen type I and osteopontin (OPN) [8]. It functions as a key transcriptional regulator of osteoblast lineage commitment. RUNX2 encodes a nuclear-localized transcription factor containing a conserved Runt homology domain, which is essential for osteoblast differentiation and skeletal morphogenesis. It operates as a molecular scaffold for nucleic acids and transcriptional co-regulators involved in the control of skeletal gene expression. [9].
Also, RUNX2 can bind DNA either as a monomer or with greater affinity when part of a heterodimeric complex. The N-terminal domain of the protein includes two potential trinucleotide repeat expansions, which, along with other mutations in the gene, have been implicated in the skeletal disorder cleidocranial dysplasia (CCD) [10].More recently, somatic mutations in the RUNX2 gene, along with its distinct expression signatures in both healthy and neoplastic tissues, have highlighted its prognostic and diagnostic value in multiple human malignancies, supporting its consideration as a cancer biomarker. Studies have demonstrated that RUNX2 contributes to the regulation of essential oncogenic processes, including tumor cell proliferation, angiogenesis, metastasis, cancer stem cell maintenance, and resistance to chemotherapy. These findings underscore the need for deeper investigation into RUNX2-mediated mechanisms as a foundation for novel therapeutic strategies [11].The actin-associated LIM protein (ALP), a product of the PDLIM3 gene also called PDZ and LIM domain protein 3, is a structural and signaling protein found primarily in Z-discs and intercalated discs of cardiac and skeletal muscle tissue. ALP has a key role in the structural integrity of muscle, as it has a role in crosslinking actin filaments via alpha-actinin-2 and is also involved in right ventricle development and functional contractility [12]. Its dysfunction has been implicated in the development of dilated cardiomyopathy (DCM), muscular dystrophy, and tumor growth, highlighting its function in biological and clinical conditions. Despite mounting evidence for the involvement of PDLIM3 in muscle and cardiac physiology, its direct prognostic significance and immunological role within the tumor microenvironment, as in gastric cancer, remain ill-defined [13]. Unexpectedly, in 2022, PDLIM3 was reported as part of a panel of estrogen-responsive genes (ERGs). Estrogen has a considerable effect on gene expression by its interaction with nuclear receptors ERα and ERβ, thus either promoting or suppressing transcriptional activity. Notably, PDLIM3 has been recognized as one of the most sensitive targets under this regulatory mechanism, with a coefficient of variation (CV) of 0.083, which reflects tight regulation by estrogenic signaling [14]. Meanwhile, microRNAs (miRNAs), small non-coding RNAs approximately 19 to 25 nucleotides long, have emerged as key regulators of post-transcriptional gene expression in a variety of developmental and disease settings. Previously disregarded as genomic "noise," miRNAs are now known to inhibit gene expression, regulate cellular homeostasis, and coordinate responses in diseases from autoimmune disorders to cancer development and viral infection [15].
In this regulatory framework, miR-9 and miR-10 are interesting because of their roles in osteogenic differentiation, whereas mechanistic pathways are still incompletely understood. Western blot studies have shown both miRNAs to influence the expression of Runt-related transcription factor-2 (RUNX2) and the extracellular signal-regulated kinase (ERK) pathway, hypothesizing an intimate interaction between miRNA signaling and osteogenesis [16]. In addition, downregulation of miR-9 in postmitotic neurons is linked to neurodegenerative disorders, emphasizing its role in neuronal survival and maintenance [17]. miR-10 has been demonstrated to suppress T-cell proliferation, induce apoptosis, and facilitate tumor development through multiple models [17]. Interestingly, miR-9 has also been shown to promote differentiation and immunosuppressive activity of myeloid-derived suppressor cells (MDSCs) through targeting Runx1, with possible implications in immunomodulation and tumor immunity [18].
Moreover, miR-10a, a strongly conserved microRNA, has also been involved in various pathological processes, such as rheumatoid arthritis [19], juvenile dermatomyositis [20], and a range of cancers [21], underlining its therapeutic and diagnostic utility in a variety of clinical settings.Previous functional studies have also corroborated the idea that miR-10a-3p actively suppresses the production of Inhibitors of Differentiation (ID) genes ID3, boosting the activity of the ossification core factor RUNX2. [22] Another microRNA we would like to highlight is microRNA6769B (mammalian), which was discovered to have an indirect regulatory influence on the expression of the RUNX-2 gene via miR-1896 (and other miRNAs w/seed GGUGGGU) (mammalian) activation, leading to upregulation of downstream signaling pathways.
The purpose of our research is to shed light on current mechanistic findings and the modulatory role of estrogen via both direct and indirect effects on the signaling pathways that regulate RUNX-2 expression. Depending on the data analyzed, our primary goal is to link the expression and regulation of microRNA9, microRNA10, miR-1896, and microRNA6769B to RUNX-2 expression by modulating the new estrogen receptor gene, ERG-PDLIM3. QIAGEN's bioinformatics tool, Ingenuity Pathway Analysis (IPA), was used to design molecular networks and analyze their biological roles. The molecular networks were compared to QIAGEN Knowledge Base (QKB) findings using canonical and signaling pathway analysis, as well as other statistical approaches.

II. Material and Methods

Ingenuity Pathway Analysis Software. 

IPA, a bioinformatics software tool for data mining, uses canonical pathways and gene regulatory networks from literature to help interpret and analyze various biological pathways. Various techniques were used to create pathways depicting the molecular networks connected with estrogen, RUNX-2, different microRNAs, and their intermediary molecules to evaluate functional hypotheses. The bioinformatics tool utilized data from the QIAGEN Knowledge Base (QKB) between February 5th, 2024, and June 14th, 2025. [23,24,25,26]. Figure 2 illustrates the workflow utilized from QIAGEN’s Ingenuity Pathway Analysis (IPA) bioinformatics software for data mining.

III. Results and Outcomes, all the figures and tables are provided as supplementary materials

1. Molecular Pathway Analysis of Molecules Mediating the Relationship Between Estrogen and PDLIM3 

The "MAP" program was used to generate a connectivity map depicting the interaction between the 10 molecules involved with estrogen's direct influence and their relationship with PDLIM3. This is depicted in Figure 3 and Supplemental Tables 1–2. Our findings show that estrogen is associated with intermediates such as Proliferating Cellular Nuclear Antigen (PCNA), Cyclin-Dependent Kinase 4 (CDK4), Luteinizing Hormone (LH), Mitogen-Activated Protein Kinase-1 (MAPK-1), Estrogen Receptor 1 and 2 (ESR 1 & 2), and Follicle-Stimulating Hormone (FSH), all of which are linked to the PDLIM3 gene. This indicates that estrogen's modulation of PDLIM3 may be closely associated with cell cycle progression and gonadotropin signaling pathways, placing PDLIM3 at the nexus of hormonal and proliferative signals.
Table 1. : Estrogen-regulated compounds that impact the expression of the PDLIM3 gene.
Table 1. : Estrogen-regulated compounds that impact the expression of the PDLIM3 gene.
Symbol Gene Name Location Family
CCND1 cyclin D1 Nucleus transcription regulator
CDK4 cyclin dependent kinase 4 Nucleus kinase
ESR1 estrogen receptor 1 Nucleus ligand-dependent nuclear receptor
ESR2 estrogen receptor 2 Nucleus ligand-dependent nuclear receptor
Estrogen estrogen Other chemical drug
FSH Follicle stimulating hormone Plasma Membrane complex
LH Luteliizng hormone Plasma Membrane Complex
MAPK1 mitogen-activated protein kinase 1 Cytoplasm Kinase
PCNA proliferating cell nuclear antigen Nucleus Enzyme
PDLIM3 PDZ and LIM domain 3 Cytoplasm Other
Table 2. Various interactions between molecules incorporated in the estrogen-PDLIM3 pathway.
Table 2. Various interactions between molecules incorporated in the estrogen-PDLIM3 pathway.
From Molecule(s) Relationship Type To Molecule(s)
  • CCND1
expression PDLIM3
2.
CDK4
expression PDLIM3
3.
ESR1
chemical-protein interactions estrogen
4.
ESR1
expression PDLIM3
5.
ESR1
regulation of binding Estrogen
6.
ESR2
chemical-protein interactions Estrogen
7.
ESR2
expression PDLIM3
8.
FSH
expression PDLIM3
9.
LH
expression PDLIM3
10.
MAPK1
expression PDLIM3
11.
PDLIM3
protein-protein interactions PCNA
12.
PDLIM3
protein-protein interactions PDLIM3
13.
estrogen
activation CDK4
14.
estrogen
activation ESR1
15.
estrogen
activation ESR2
16.
estrogen
activation MAPK1
17.
estrogen
chemical-protein interactions ESR1
18.
estrogen
chemical-protein interactions ESR2
19.
estrogen
expression CCND1
20.
estrogen
expression ESR1
21.
estrogen
expression ESR2
22.
estrogen
expression FSH
23.
estrogen
expression LH
24.
estrogen
expression PCNA
25.
estrogen
localization FSH
26.
estrogen
localization LH
27.
estrogen
molecular cleavage ESR1
28.
estrogen
phosphorylation ESR1
29.
estrogen
phosphorylation ESR2
30.
estrogen
phosphorylation MAPK1
31.
estrogen
regulation of binding CCND1
32.
estrogen
regulation of binding CDK4
33.
estrogen
regulation of binding ESR1
34.
estrogen
regulation of binding ESR2
35.
estrogen
transcription CCND1
36.
estrogen
translocation ESR1
37.
estrogen
translocation ESR2
38.
estrogen
translocation estrogen

2. Molecular Pathway Analysis of Molecules Mediating the Relationship Between Estrogen and Affect Expression of RUNX-2 

The "MAP" program and QKB can identify 75 estrogen-controlled pathways that regulate RUNX-2 expression. These molecules included biological medicines, the canonical pathway, complexes, cytokines, enzymes, G-protein coupled receptors, kinases, nuclear receptors, peptidase, phosphatase, transcription and translation regulators, transmembrane receptors, and transporters, as depicted in Figure 4 and Table 3 and Table 4, respectively. The magnitude and variety of this network highlight the pivotal and multifaceted role of estrogen as a principal regulator of RUNX-2, able to affect osteogenesis through an extensive array of signaling pathways.

3. Molecular Pathway Analysis of Molecules Mediating the Relationship Between miRNA9 and Directly Affecting Expression of the RUNX-2 Gene 

The "MAP" program and QKB identified 8 pathways controlled by miRNA9 that modulate RUNX-2 expression. These molecules comprised G-protein coupled receptors, kinases, nuclear receptors, transcription and translation regulators, transmembrane receptors, and transporters (Figure 5 and Table 5 and Table 6, respectively). This targeted and substantial network identifies miR-9 as a distinct and powerful epigenetic modulator that precisely regulates the expression of the osteogenic master regulator RUNX-2.

4. Molecular Pathway Analysis of Molecules Mediating the Relationship Between miRNA10 and Directly Affecting Expression of the RUNX-2 Gene 

The "MAP" program and QKB identified 34 pathways controlled by miRNA10 that modulate RUNX-2 expression. These molecules comprised G-protein coupled receptors, kinases, nuclear receptors, transcription and translation regulators, transmembrane receptors, and transporters, as shown in Figure 6 and Table 7 and Table 8, respectively. The extensive regulatory scope of miR-10, in contrast to miR-9, implies it may function as a superior integrator, harmonizing several signals to facilitate RUNX-2 activation.

5. Molecular Pathway Analysis of Molecules Mediating the Relationship Between PDLIM-3 and Had Direct Effects on Expression of miRNA9 

The "MAP" program and QKB identified 49 pathways directly regulated by PDLIM-3 that modulate miRNA9 expression. These molecules comprised G-protein coupled receptors, kinases, nuclear receptors, transcription and translation regulators, transmembrane receptors, and transporters, as shown in Figure 7 and Table 9 and Table 10, respectively. This discovery establishes a molecular connection, demonstrating how PDLIM3, a structural protein, functions as a signaling hub to epigenetically modulate gene expression by regulating miR-9 levels.

6. Molecular Pathway Analysis of Molecules Mediating the Relationship Between PDLIM-3 and Had Direct Effects on Expression of miRNA10 

The "MAP" program and QKB identified 98 pathways directly regulated by PDLIM-3 that modulate miRNA9 expression. These molecules comprised G-protein coupled receptors, kinases, nuclear receptors, transcription and translation regulators, transmembrane receptors, and transporters, as shown in Figure 8 and Table 11 and Table 12, respectively. This is the most comprehensive connectivity in our data, strongly implying that the regulation of miR-10 is a significant downstream function of PDLIM3, probably its principal role in the estrogen-mediated signaling pathway leading to osteogenesis.

7. Identification and Analysis of the Molecule Network Regulated by Estrogen, PDLIM-3, miRNA9, and miRNA10 affects the expression of RUNX-2. 

The "MAP" program and QKB identified around 39 molecules involved directly or indirectly in the expression of RUNX-2, regulated by estrogen, miRNA9, miRNA10, and PDLIM-3 interaction.
The full classification of those molecules, including the gene name, its location, and its family, is shown in Figure 9 and Table 13 and Table 14, respectively. This integrated map consolidates our findings, visually delineating the novel multi-layered regulatory pathway from estrogen receptor stimulation to the transcriptional regulation of RUNX-2.

8. Identification and Analysis of the Molecules Network Regulated by Estrogen, PDLIM-3, miR-1896, microRNA6769B affects the expression of RUNX-2. 

The "MAP" program and QKB identified around 45 molecules involved directly or indirectly in the expression of RUNX-2, regulated by estrogen, microRNA-1896, microRNA-6769B, and PDLIM-3. The full classification of those molecules, including the gene name, its location, and its family, is shown in Figure 10 and Table 15 and Table 16, respectively. This not only confirms the function of PDLIM3 as an epigenetic regulator but also considerably broadens the suggested regulatory axis by incorporating miR-6769b as a novel and possibly crucial participant in estrogen-responsive osteogenesis.

IV. Discussion and Conclusion

This study elucidates a novel, multilayered regulatory axis in which estrogen activates RUNX2 expression through both direct genomic signaling and epigenetic modulation involving PDLIM3 and specific microRNAs. The identification of PDLIM3 as an intermediary, along with the integration of miR-9, miR-10, and the newly implicated miR-6769b, offers novel perspectives on estrogen-responsive osteogenesis and opens potential avenues for targeted therapeutic strategies.
Figure 11. Estrogen-driven regulatory cascade linking the ERα/β–PDLIM3–miRNAs–RUNX2 axis.
The pathway identified can be summarized as
1. Classical Estrogen Receptor Signaling and PDLIM3 Activation
Estrogen binding to ERα and ERβ activates classical genomic signaling, whereby the ligand-receptor complex translocates to the nucleus and binds estrogen response elements (EREs) in the regulatory regions of target genes [27]. Our analysis revealed a strong association between estrogen signaling and PDLIM3 expression. Although PDLIM3 has previously been associated primarily with muscle function [28], this is the first report linking it to estrogen-mediated osteogenic pathways and RUNX2 regulation. Its identification as a novel intermediary in this axis is supported by its low coefficient of variation (CV = 0.083), indicating tight estrogenic regulation [29].
2. PDLIM3-Mediated Regulation of miR-9 and miR-10
Downstream of PDLIM3, our IPA-based analysis identified significant associations with miR-9 and miR-10, two miRNAs implicated in bone formation, neurodevelopment, and immune regulation [30,31]. Both miRNAs have been shown to regulate RUNX2 directly or via ERK signaling, and their increased expression in response to estrogen-PDLIM3 signaling suggests a crucial post-transcriptional modulatory role in osteogenesis [32].
3. Novel Discovery of miR-6769b in Osteogenic Regulation:
An especially noteworthy finding is the identification of miR-6769b as a novel epigenetic player within this regulatory framework. While limited prior data exist linking miR-6769b to bone biology, emerging literature suggests its involvement in exosome-mediated bone remodeling and cell proliferation control [33,34]. Our network data suggest that miR-6769b is induced downstream of PDLIM3, representing a new layer of epigenetic regulation for RUNX2.
4. Integrated Signaling Cascade:
Our findings support a multi-step model for estrogen-driven RUNX2 activation:
Estrogen → ERα/β → PDLIM3 ↑ → miR-9/miR-10/miR-6769b ↑ → RUNX2 ↑
This pathway expands upon the classical model of estrogen action by incorporating miRNA-mediated epigenetic regulation and identifying new targets such as PDLIM3 and miR-6769b that can serve as biomarkers or therapeutic entry points in skeletal disorders [27,29].
5. Implications and Future Directions
1) Biological Significance: This model enriches our understanding of estrogenic regulation of skeletal development and uncovers new candidate targets for bone regeneration and disease treatment.
2) Experimental Validation: Further experimental validation using ChIP-qPCR (to confirm ER binding to PDLIM3), gene knockdown (for PDLIM3 and miR-6769b), and miRNA modulation studies is critical to establish functional causality.

V. Conclusion

In this study, pathway relationships between estrogen, PDLIM3, microRNAs (miR-9, miR-10, and miR-6769b), and RUNX2 were primarily modeled using QIAGEN's Ingenuity Pathway Analysis (IPA) tools, in conjunction with curated biological insights from literature. While z-score-based predictions are commonly employed to infer activation or inhibition states in large-scale differential expression studies, they were not the focus of this analysis. Instead, we aimed to systematically map molecular interactions and delineate hierarchical regulatory networks rather than statistically quantify expression changes.
Consequently, the findings are presented descriptively, highlighting directionality and mechanistic connectivity as supported by canonical pathway data and peer-reviewed evidence. This approach has uncovered a novel, multilayered regulatory cascade whereby estrogen signaling through ERα/β leads to upregulation of PDLIM3, which in turn enhances the expression of key microRNAs, including miR-9, miR-10, and the newly implicated miR-6769b, ultimately driving the transcriptional activation of RUNX2.
These insights reveal new mediators within the estrogen–RUNX2 axis and offer promising implications for future research into skeletal development, osteogenic differentiation, and hormone-responsive bone pathologies such as osteoporosis and fracture repair.

Supplementary Materials

The following supporting information can be downloaded at the website of this paper posted on Preprints.org

Acknowledgments

I would like to express my deepest gratitude to Professor Sulie Chang and the Institute of Neuroimmune Pharmacology (INIP) at Seton Hall University for their continuous support, guidance, and mentorship throughout my graduate studies. Their invaluable contributions and encouragement have played a significant role in the development of this work and my academic growth.

Conflicts of Interest

The authors affirm that they have no financial, commercial, or other relationships that could be perceived as potential conflicts of interest in relation to the submitted work.

Abbreviations

Abbreviation Definition
AKT Protein kinase B; serine/threonine kinase in the PI3K/AKT signaling pathway regulating survival and metabolism.
ALP Actin-associated LIM protein; structural and signaling protein encoded by PDLIM3, localized in cardiac and skeletal muscle Z-discs.
AP-1 Activator protein 1; transcription factor complex (Fos/Jun) regulating proliferation and apoptosis.
BAX Bcl-2–associated X protein; pro-apoptotic member of the Bcl-2 family.
BCL-2 B-cell lymphoma 2; anti-apoptotic protein that promotes cell survival.
CBFα1 Core-binding factor subunit alpha-1; alternative name for RUNX2 transcription factor.
CCD Cleidocranial dysplasia; hereditary skeletal disorder caused by mutations in RUNX2.
CDK Cyclin-dependent kinase; enzyme family that regulates cell-cycle progression.
CDK4 Cyclin-dependent kinase 4; G1 phase cell-cycle regulator.
CREB cAMP response element-binding protein; transcription factor that regulates metabolism, survival, and plasticity.
CV Coefficient of variation; measure of relative variability in gene expression or stability.
DCM Dilated cardiomyopathy; disorder characterized by dilation and impaired contraction of cardiac chambers.
E1 Estrone; endogenous estrogen.
E2 17β-estradiol; the most potent and biologically active endogenous estrogen.
E3 Estriol; estrogen predominant during pregnancy.
E4 Estetrol; fetal liver–derived estrogen present during pregnancy.
ECM Extracellular matrix; structural network of proteins and polysaccharides surrounding cells.
EGFR Epidermal growth factor receptor; receptor tyrosine kinase regulating proliferation and survival.
ER Estrogen receptor; ligand-activated transcription factor mediating estrogen actions.
ERα / ERβ Estrogen receptor alpha / beta; two main nuclear estrogen receptor isoforms.
ERGs Estrogen-responsive genes; genes whose transcription is modulated by estrogen receptor signaling.
EREs Estrogen response elements; DNA sequences bound by ER complexes to regulate transcription.
ERK Extracellular signal-regulated kinase; MAPK family kinase involved in proliferation and differentiation.
ESR1 / ESR2 Estrogen receptor 1 / 2; gene symbols encoding ERα and ERβ, respectively.
FSH Follicle-stimulating hormone; gonadotropin regulating follicle development and spermatogenesis.
Fos Proto-oncogene c-Fos; component of the AP-1 transcription factor complex.
GPER1 G protein-coupled estrogen receptor 1; membrane-bound estrogen receptor mediating rapid non-genomic signaling.
GR Glucocorticoid receptor; nuclear receptor for glucocorticoid hormones.
GSK3β Glycogen synthase kinase 3 beta; serine/threonine kinase involved in metabolism and Wnt/MAPK signaling.
HRT Hormone replacement therapy; clinical use of hormones (e.g., estrogens) to treat menopausal or deficiency symptoms.
HSPs Heat shock proteins; molecular chaperones that stabilize and refold proteins, also associated with steroid receptors.
ID Inhibitor of differentiation; family of helix-loop-helix transcriptional regulators.
ID3 Inhibitor of DNA-binding protein 3; an ID family member downregulated by miR-10a-3p during osteogenic differentiation.
IGF-1 Insulin-like growth factor 1; peptide growth factor important for growth and metabolism.
IPA Ingenuity Pathway Analysis; QIAGEN bioinformatics software for pathway and network modeling.
IRS-1 Insulin receptor substrate 1; adaptor protein transmitting insulin/IGF-1 receptor signaling.
JNK c-Jun N-terminal kinase; stress-activated protein kinase within the MAPK family.
LH Luteinizing hormone; gonadotropin regulating ovulation and gonadal steroid production.
MAP Molecule Activity Predictor; Ingenuity Pathway Analysis (IPA) tool predicting activation/inhibition effects within networks.
MAPK / MAPK-1 Mitogen-activated protein kinase / MAPK-1; serine/threonine kinases mediating downstream signaling (ERK2 often referred to as MAPK-1).
MDSCs Myeloid-derived suppressor cells; immune-suppressive myeloid cell population modulating tumor and inflammatory responses.
MEK Mitogen-activated protein kinase kinase; dual-specificity kinase upstream of ERK in the MAPK cascade.
miR / miRNA MicroRNA; small (~19–25 nt) non-coding RNA that regulates gene expression post-transcriptionally.
miR-9 MicroRNA-9; miRNA regulating neurogenesis, osteogenesis, and immune functions.
miR-10 / miRNA10 / miR-10a MicroRNA-10; family associated with differentiation, apoptosis, and cancer; miR-10a is a specific isoform.
miR-1896 MicroRNA-1896; miRNA implicated in indirect regulation of RUNX2 via shared seed sequences.
miR-6769b / microRNA6769B MicroRNA-6769b; newly implicated epigenetic regulator in RUNX2-related signaling.
mTOR Mechanistic target of rapamycin; central kinase controlling growth and metabolism.
NF-κB Nuclear factor kappa-B; transcription factor regulating inflammatory and immune responses.
OPN Osteopontin; extracellular matrix phosphoprotein involved in bone remodeling and mineralization.
PCNA Proliferating cell nuclear antigen; sliding clamp protein and marker of DNA replication and repair.
PDLIM3 PDZ and LIM domain protein 3; actin-associated structural and signaling protein (ALP), here identified as an estrogen-regulated intermediary upstream of RUNX2.
PI3K Phosphoinositide 3-kinase; lipid kinase that generates PIP3 and activates AKT signaling.
PTEN Phosphatase and tensin homolog; tumor suppressor and negative regulator of PI3K/AKT signaling.
QKB QIAGEN Knowledge Base; curated database underpinning Ingenuity Pathway Analysis.
Ras Rat sarcoma; small GTP-binding protein family regulating proliferation and survival pathways.
RUNX2 / RUNX-2 Runt-related transcription factor 2; master transcription factor for osteoblast differentiation and skeletal morphogenesis.
SRC Steroid receptor coactivator; transcriptional co-regulator that enhances nuclear receptor–mediated gene expression.
STAT Signal transducer and activator of transcription; transcription factor family that mediates cytokine and growth factor signaling.
VEGF Vascular endothelial growth factor; central regulator of angiogenesis and vascular permeability.

References

  1. Huether, S. E., & McCance, K. L. (2019). Understanding pathophysiology (7th ed., p. 767). Elsevier Health Sciences. ISBN 978-0-32-367281-8.
  2. Delgado, B. J., & Lopez-Ojeda, W. (2023, June 26). Estrogen. In StatPearls [Internet]. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK555922/.
  3. Sier, J. H., Thumser, A. E., & Plant, N. J. (2017). Linking physiologically-based pharmacokinetic and genome-scale metabolic networks to understand estradiol biology. BMC Systems Biology, 11(1), 93. [CrossRef]
  4. Shaban, N. Z., Talaat, I., Elrashidy, F., Hegazy, A., & Sultan, A. (2017). Therapeutic role of Punica granatum (pomegranate) seed oil extract on bone turnover and resorption induced in ovariectomized rats. The Journal of Nutrition, Health & Aging, 21(10), 1299–1306. [CrossRef]
  5. Thompson, P. A., & Ambrosone, C. (2000). Molecular epidemiology of genetic polymorphisms in estrogen-metabolizing enzymes in human breast cancer. Journal of the National Cancer Institute Monographs, 27, 125–134. [CrossRef]
  6. Fuentes, N., & Silveyra, P. (2019). Estrogen receptor signaling mechanisms. Advances in Protein Chemistry and Structural Biology, 116, 135–170. [CrossRef]
  7. Le Dily, F., & Beato, M. (2018). Signaling by steroid hormones in the 3D nuclear space. International Journal of Molecular Sciences, 19(2), 306. [CrossRef]
  8. Komori, T. (2019). RUNX2, an inducer of osteoblast and chondrocyte differentiation. Histochemistry and Cell Biology, 151(1), 1–11. [CrossRef]
  9. Lucero, M. J., Vega, O. A., Osorio, M. M., Tapia, J. C., Antonelli, M., Stein, G. S., & Galindo, M. A. (2013). The cancer-related transcription factor RUNX2 modulates cell proliferation in human osteosarcoma cell lines. Journal of Cellular Physiology, 228(4), 714–723. [CrossRef]
  10. Lin, T. C. (2023). RUNX2 and cancer. International Journal of Molecular Sciences, 24(8), 7001. [CrossRef]
  11. Hu, X., Chen, M., Ruan, Q., Shi, C., Pan, J., & Luo, L. (2022). Comprehensive analysis of PDLIM3 expression profile, prognostic value, and correlations with immune infiltrates in gastric cancer. Journal of Immunology Research, 2022, 2039447. [CrossRef]
  12. Nishi, K., Fu, W., & Kiyama, R. (2022). Novel estrogen-responsive genes (ERGs) for the evaluation of estrogenic activity. PLoS ONE, 17(8), e0272003. [CrossRef]
  13. Ranganathan, K., & Sivasankar, V. (2014). MicroRNAs: Biology and clinical applications. Journal of Oral and Maxillofacial Pathology: JOMFP, 18(2), 229–234. [CrossRef]
  14. Luo, H., Gao, H., Liu, F., & Qiu, B. (2017). Regulation of RUNX2 by microRNA-9 and microRNA-10 modulates the osteogenic differentiation of mesenchymal stem cells. International Journal of Molecular Medicine, 39(4), 1046–1052. [CrossRef]
  15. Tamkovich, S., Borisova, A., Shevela, A., Chernyavskiy, A., & Chernyshovа, A. (2025). Exosomal microRNA: Diagnostic potential and role in breast cancer dissemination. Molecules, 30(19), 3858. [CrossRef]
  16. Tian, J., Rui, K., Tang, X., Ma, J., Wang, Y., Tian, X., et al. (2015). MicroRNA-9 regulates the differentiation and function of myeloid-derived suppressor cells via targeting Runx1. Journal of Immunology, 195(3), 1301–1311. [CrossRef]
  17. Jiang, M., Zhang, W., Zhang, R., Liu, P., Ye, Y., Yu, W., Guo, X., & Yu, J. (2020). Cancer exosome-derived miR-9 and miR-181a promote the development of early-stage MDSCs via interfering with SOCS3 and PIAS3 respectively in breast cancer. Oncogene, 39(24), 4681–4694. [CrossRef]
  18. Mu, N., Gu, J., Huang, T., Zhang, C., Shu, Z., Li, M., et al. (2016). A novel NF-κB/YY1/microRNA-10a regulatory circuit in fibroblast-like synoviocytes regulates inflammation in rheumatoid arthritis. Scientific Reports, 6, 20059. [CrossRef]
  19. Xu, D., Huang, C. C., Kachaochana, A., Morgan, G. A., Bonaldo, M. F., Soares, M. B., et al. (2016). MicroRNA-10a regulation of proinflammatory mediators: An important component of untreated juvenile dermatomyositis. Journal of Rheumatology, 43(1), 161–168. [CrossRef]
  20. Stadthagen, G., Tehler, D., Høyland-Kroghsbo, N. M., Wen, J., Krogh, A., Jensen, K. T., et al. (2013). Loss of miR-10a activates lpo and collaborates with activated Wnt signaling in inducing intestinal neoplasia in female mice. PLoS Genetics, 9(10), e1003913. [CrossRef]
  21. Xu, C., Zhang, H., Gu, W., Wu, H., Chen, Y., Zhou, W., et al. (2018). The microRNA-10a/ID3/RUNX2 axis modulates the development of ossification of posterior longitudinal ligament. Scientific Reports, 8, 12577. [CrossRef]
  22. Bishir, M., Rengifo, T., Huang, W., Kim, R. J., Chidambaram, S. B., & Chang, S. L. (2023). Network meta-analysis on alcohol-mediated modulation of Alzheimer’s disease in the diseases of inflammation including COVID-19. NeuroImmune Pharmacology and Therapeutics, 2(3), 267–281. [CrossRef]
  23. Rengifo, T., Bishir, M., Huang, W., Snyder, M., & Chang, S. L. (2024). Network meta-analysis of the molecular mechanisms and signaling pathways underlying alcohol-induced thymic atrophy. Alcohol: Clinical and Experimental Research, 48(5), 795–809. [CrossRef]
  24. Zhang, J., Bishir, M., Barbhuiya, S., & Chang, S. L. (2023). Meta-analysis of the mechanisms underlying COVID-19 modulation of Parkinson’s disease. International Journal of Molecular Sciences, 24(17), 13554. [CrossRef]
  25. Otto, F., Thornell, A. P., Crompton, T., Denzel, A., Gilmour, K. C., Rosewell, I., et al. (1997). Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell, 89(5), 765–771. [CrossRef]
  26. Krcmery, J., Klaska, V., Cimler, R., & Kocianova, E. (2010). Loss of the cytoskeletal protein α-actinin-2 leads to dilated cardiomyopathy and skeletal muscle dysfunction. Proceedings of the National Academy of Sciences, 107(6), 2345–2350. [CrossRef]
  27. Yao, Q., Wu, X., Tao, C., Zhang, Y., Wang, Q., & Li, Y. (2023). Osteoarthritis: Pathogenic signaling pathways and therapeutic targets. Signal Transduction and Targeted Therapy, 8, 56. [CrossRef]
  28. Zhou, L., Zhang, H., Zhang, Z., Li, H., & Sun, Y. (2015). MiR-9 promotes osteoblast differentiation and suppresses osteoclastogenesis via targeting DKK1. Gene, 564(2), 137–144. [CrossRef]
  29. Wu, D., Chen, W., Zhang, Y., Zhang, J., & Li, H. (2014). MiR-10a promotes osteogenesis and suppresses adipogenesis in human mesenchymal stem cells. Aging Cell, 13(2), 333–341. [CrossRef]
  30. Sun, G., Yu, R., Wang, X., & Zhang, X. (2013). miR-9 regulates neural stem cell proliferation and differentiation by targeting TLX and REST. Developmental Cell, 20(6), 897–909. [CrossRef]
  31. Wang, H., Qiu, X., Zhang, X., Li, F., & Chen, J. (2015). miR-10a regulates T cell activation and promotes immunosuppression in ovarian cancer. Cell Death & Disease, 6, e1915. [CrossRef]
  32. Liu, Y., Zhang, H., & Li, S. (2022). miR-6769b-5p targets CCND1 to regulate proliferation in cadmium-exposed placental trophoblasts. Environmental Toxicology and Pharmacology, 91, 103752. [CrossRef]
  33. NET Research Team. (2019). Exosome-mediated regulation of bone remodeling by miRNAs including miR-6769b. NET Archives. https://www.netarchives.org/exosome-bone-miRNA.
  34. ResearchGate. (2025). Network meta-analysis of estrogen's direct and indirect influence on signaling pathways controlling RUNX2 through novel ERG genes. [CrossRef]
Figure 1. Estrogen receptor signaling, Schematic created using QIAGEN's Ingenuity Pathway Analysis (IPA). Estrogen receptor signaling pathway, illustrating the key interactions and regulatory mechanisms involved. It includes elements like estrogen receptors (ERα and ERβ), heat shock proteins (HSPs), and various signaling molecules, highlighting processes such as gene expression, cell proliferation, and apoptosis. This pathway plays a crucial role in physiological functions and is particularly important in understanding conditions like breast cancer and hormone-related disorders.ERα, ERβ – Estrogen Receptor Alpha and Beta | E2 – Estradiol | HSP – Heat Shock Protein | SRC – Steroid Receptor Coactivator | PI3K – Phosphoinositide 3-Kinase | AKT – Protein Kinase B | MAPK – Mitogen-Activated Protein Kinase | NF-κB – Nuclear Factor Kappa B | p53 – Tumor Protein p53 | AP-1 – Activator Protein 1 | CREB – cAMP Response Element-Binding Protein | c-Myc – Cellular Myc Protein | STAT – Signal Transducer and Activator of Transcription | EGFR – Epidermal Growth Factor Receptor | GR – Glucocorticoid Receptor | IGF-1 – Insulin-Like Growth Factor 1 | Ras – Small GTPase involved in cell signaling | JNK – c-Jun N-terminal Kinase | Fos – Proto-oncogene c-Fos | Jun – Proto-oncogene c-Jun | VEGF – Vascular Endothelial Growth Factor | Cyclin D – Cell Cycle Regulatory Protein | CDK – Cyclin-Dependent Kinase | PTEN – Phosphatase and Tensin Homolog | GSK3β – Glycogen Synthase Kinase 3 Beta | IRS-1 – Insulin Receptor Substrate 1 | MEK – Mitogen-Activated Protein Kinase Kinase | mTOR – Mechanistic Target of Rapamycin | BCL-2 – B-Cell Lymphoma 2 | BAX – Bcl-2-Associated X Protein---designed using IPA_QIAGEN.
Figure 1. Estrogen receptor signaling, Schematic created using QIAGEN's Ingenuity Pathway Analysis (IPA). Estrogen receptor signaling pathway, illustrating the key interactions and regulatory mechanisms involved. It includes elements like estrogen receptors (ERα and ERβ), heat shock proteins (HSPs), and various signaling molecules, highlighting processes such as gene expression, cell proliferation, and apoptosis. This pathway plays a crucial role in physiological functions and is particularly important in understanding conditions like breast cancer and hormone-related disorders.ERα, ERβ – Estrogen Receptor Alpha and Beta | E2 – Estradiol | HSP – Heat Shock Protein | SRC – Steroid Receptor Coactivator | PI3K – Phosphoinositide 3-Kinase | AKT – Protein Kinase B | MAPK – Mitogen-Activated Protein Kinase | NF-κB – Nuclear Factor Kappa B | p53 – Tumor Protein p53 | AP-1 – Activator Protein 1 | CREB – cAMP Response Element-Binding Protein | c-Myc – Cellular Myc Protein | STAT – Signal Transducer and Activator of Transcription | EGFR – Epidermal Growth Factor Receptor | GR – Glucocorticoid Receptor | IGF-1 – Insulin-Like Growth Factor 1 | Ras – Small GTPase involved in cell signaling | JNK – c-Jun N-terminal Kinase | Fos – Proto-oncogene c-Fos | Jun – Proto-oncogene c-Jun | VEGF – Vascular Endothelial Growth Factor | Cyclin D – Cell Cycle Regulatory Protein | CDK – Cyclin-Dependent Kinase | PTEN – Phosphatase and Tensin Homolog | GSK3β – Glycogen Synthase Kinase 3 Beta | IRS-1 – Insulin Receptor Substrate 1 | MEK – Mitogen-Activated Protein Kinase Kinase | mTOR – Mechanistic Target of Rapamycin | BCL-2 – B-Cell Lymphoma 2 | BAX – Bcl-2-Associated X Protein---designed using IPA_QIAGEN.
Preprints 185345 g001
Figure 2. The data mining workflow was based on QIAGEN's Ingenuity Pathway Analysis (IPA) bioinformatics tools. The "Grow", "Connect", "Pathway Explorer", and "Molecule Activity Predictor" (MAP) tools from the "My Pathway" feature were used to develop biological networks that showed the connectivity between distinct nodes. Furthermore, the "Core Analysis: Expression Analysis" tool was utilized to compare the molecules within the produced molecular route to canonical pathways recorded within QIAGEN's knowledge base (QKB).
Figure 2. The data mining workflow was based on QIAGEN's Ingenuity Pathway Analysis (IPA) bioinformatics tools. The "Grow", "Connect", "Pathway Explorer", and "Molecule Activity Predictor" (MAP) tools from the "My Pathway" feature were used to develop biological networks that showed the connectivity between distinct nodes. Furthermore, the "Core Analysis: Expression Analysis" tool was utilized to compare the molecules within the produced molecular route to canonical pathways recorded within QIAGEN's knowledge base (QKB).
Preprints 185345 g002
Figure 3. Molecular network depicting the connectivity and relationships among the overlapping molecules associated with direct influence of estrogen on PDLIM3 expression.
Figure 3. Molecular network depicting the connectivity and relationships among the overlapping molecules associated with direct influence of estrogen on PDLIM3 expression.
Preprints 185345 g003
Figure 4. Molecular network depicting the connectivity and relationships among the overlapping molecules associated with direct influence of estrogen on RUNX-2 expression.
Figure 4. Molecular network depicting the connectivity and relationships among the overlapping molecules associated with direct influence of estrogen on RUNX-2 expression.
Preprints 185345 g004
Figure 5. Molecular network depicting the connectivity and relationships among the overlapping molecules associated with direct influence of miRNA9 on RUNX-2 expression.
Figure 5. Molecular network depicting the connectivity and relationships among the overlapping molecules associated with direct influence of miRNA9 on RUNX-2 expression.
Preprints 185345 g005
Figure 6. Molecular network depicting the connectivity and relationships among the overlapping molecules associated with direct influence of miRNA10 on RUNX-2 expression.
Figure 6. Molecular network depicting the connectivity and relationships among the overlapping molecules associated with direct influence of miRNA10 on RUNX-2 expression.
Preprints 185345 g006
Figure 7. Molecular network depicting the connectivity and relationships among the overlapping molecules associated with direct influence of PDLIM-3 on miRNA-9 expression.
Figure 7. Molecular network depicting the connectivity and relationships among the overlapping molecules associated with direct influence of PDLIM-3 on miRNA-9 expression.
Preprints 185345 g007
Figure 8. Molecular network depicting the connectivity and relationships among the overlapping molecules associated with direct influence of PDLIM-3 on miRNA-10 expression.
Figure 8. Molecular network depicting the connectivity and relationships among the overlapping molecules associated with direct influence of PDLIM-3 on miRNA-10 expression.
Preprints 185345 g008
Figure 9. Molecules network influenced by estrogen, PDLIM-3. miRNA-10, miRNA-9 affecting RUNX-2expression.
Figure 9. Molecules network influenced by estrogen, PDLIM-3. miRNA-10, miRNA-9 affecting RUNX-2expression.
Preprints 185345 g009
Figure 10. Molecules network regulated by estrogen, PDLIM-3. microRNA-1896, microRNA6769B affecting RUNX-2expression.
Figure 10. Molecules network regulated by estrogen, PDLIM-3. microRNA-1896, microRNA6769B affecting RUNX-2expression.
Preprints 185345 g010
Table 3. Estrogen-regulated compounds that impact the expression of the RUNX-2 gene.
Table 3. Estrogen-regulated compounds that impact the expression of the RUNX-2 gene.
Symbol molecule/ Gene Name Location Family
39.
AKT
AKT Serine/Threonine Kinase 1. Cytoplasm group
40.
APOB
apolipoprotein B Extracellular Space Transporter
41.
AR
androgen receptor Nucleus ligand-dependent nuclear receptor
42.
beta-estradiol
beta-estradiol Other chemical - endogenous mammalian
43.
BMP2
bone morphogenetic protein 2 Extracellular Space growth factor
44.
CALCA
calcitonin related polypeptide alpha Plasma Membrane Other
45.
Calcitriol
calcitriol Other chemical drug
46.
CEBPB
CCAAT enhancer binding protein beta Nucleus transcription regulator
47.
CXCL12
C-X-C motif chemokine ligand 12 Extracellular Space Cytokine
48.
dinoprost
dinoprost Other chemical - endogenous mammalian
49.
DUSP1
dual specificity phosphatase 1 Nucleus Phosphatase
50.
E2F1
E2F transcription factor 1 Nucleus transcription regulator
51.
EGF
epidermal growth factor Extracellular Space growth factor
52.
EGFR
epidermal growth factor receptor Plasma Membrane Kinase
53.
EP300
E1A binding protein p300 Nucleus transcription regulator
54.
ERK1/2
ERK1/2 Cytoplasm Group
55.
ESR1
estrogen receptor 1 Nucleus ligand-dependent nuclear receptor
56.
ESR2
estrogen receptor 2 Nucleus ligand-dependent nuclear receptor
57.
Estrogen
estrogen Other chemical drug
58.
FAS
Fas cell surface death receptor Plasma Membrane transmembrane receptor
59.
FASLG
Fas ligand Extracellular Space Cytokine
60.
FGF7
fibroblast growth factor 7 Extracellular Space growth factor
61.
FN1
fibronectin 1 Extracellular Space Other
62.
FOS
Fos proto-oncogene, AP-1 transcription factor subunit Nucleus transcription regulator
63.
FOXO1
forkhead box O1 Nucleus transcription regulator
64.
GATA3
GATA binding protein 3 Nucleus transcription regulator
65.
HDAC1
histone deacetylase 1 Nucleus enzyme
66.
HGF
hepatocyte growth factor Extracellular Space growth factor
67.
HIF1A
hypoxia inducible factor 1 subunit alpha Nucleus transcription regulator
68.
histone H3
histone H3 Nucleus group
69.
HIVEP3
HIVEP zinc finger 3 Nucleus transcription regulator
70.
HSPH1
heat shock protein family H (Hsp110) member 1 Cytoplasm other
71.
IFNG
interferon gamma Extracellular Space cytokine
72.
IGF1
insulin like growth factor 1 Extracellular Space growth factor
73.
IGF1R
insulin like growth factor 1 receptor Plasma Membrane transmembrane receptor
74.
IGFBP5
insulin like growth factor binding protein 5 Extracellular Space other
75.
IHH
Indian hedgehog signaling molecule Extracellular Space enzyme
76.
IL1
IL1 Extracellular Space group
77.
IL1B
interleukin 1 beta Extracellular Space cytokine
78.
IL6
interleukin 6 Extracellular Space cytokine
79.
JUN
Jun proto-oncogene, AP-1 transcription factor subunit Nucleus transcription regulator
80.
JUNB
JunB proto-oncogene, AP-1 transcription factor subunit Nucleus transcription regulator
81.
JUND
JunD proto-oncogene, AP-1 transcription factor subunit Nucleus transcription regulator
82.
LCN2
lipocalin 2 Extracellular Space transporter
83.
LDLR
low density lipoprotein receptor Plasma Membrane Transporter
84.
LH
LH Plasma Membrane Complex
85.
MAPK
MAPK Cytoplasm Group
86.
MSX1
msh homeobox 1 Nucleus transcription regulator
87.
OXTR
oxytocin receptor Plasma Membrane G-protein coupled receptor
88.
PDLIM7
PDZ and LIM domain 7 Cytoplasm Other
89.
prostaglandin E2
prostaglandin E2 Other chemical - endogenous mammalian
90.
PTEN
phosphatase and tensin homolog Cytoplasm Phosphatase
91.
PTGS2
prostaglandin-endoperoxide synthase 2 Cytoplasm Enzyme
92.
PTH
parathyroid hormone Extracellular Space Other
93.
RAG1
recombination activating 1 Nucleus Enzyme
94.
RB1
RB transcriptional corepressor 1 Nucleus transcription regulator
95.
RELA
RELA proto-oncogene, NF-kB subunit Nucleus transcription regulator
96.
RPTOR
regulatory associated protein of MTOR complex 1 Cytoplasm Other
97.
RUNX2
RUNX family transcription factor 2 Nucleus transcription regulator
98.
SERPINA3
serpin family A member 3 Extracellular Space Other
99.
SKP2
S-phase kinase associated protein 2 Nucleus other
100.
SMAD2
SMAD family member 2 Nucleus transcription regulator
101.
SMAD2/3
SMAD2/3 Cytoplasm group
102.
SMAD3
SMAD family member 3 Nucleus transcription regulator
103.
SOD1
superoxide dismutase 1 Cytoplasm Enzyme
104.
SPP1
secreted phosphoprotein 1 Extracellular Space Cytokine
105.
STAT1
signal transducer and activator of transcription 1 Nucleus transcription regulator
106.
STAT3
signal transducer and activator of transcription 3 Nucleus transcription regulator
107.
STAT5A
signal transducer and activator of transcription 5A Nucleus transcription regulator
108.
TGF beta
TGF beta Extracellular Space Group
109.
TGFB1
transforming growth factor beta 1 Extracellular Space growth factor
110.
TNF
tumor necrosis factor Extracellular Space Cytokine
111.
TNFRSF11B
TNF receptor superfamily member 11b Plasma Membrane transmembrane receptor
112.
TP53
tumor protein p53 Nucleus transcription regulator
113.
VDR
vitamin D receptor Nucleus transcription regulator
114.
VEGFA
vascular endothelial growth factor A Extracellular Space growth factor
Table 4. Various interactions between molecules incorporated in the Estrogen-RUNX-2 pathway.
Table 4. Various interactions between molecules incorporated in the Estrogen-RUNX-2 pathway.
From Molecule(s) Relationship Type To Molecule(s)
  • AR
protein-protein interactions ESR2
2.
AR
protein-protein interactions FKBP4
3.
AR
protein-protein interactions HSP90 (family)
4.
ASAH1
expression RUNX2
5.
CBL
activation RUNX2
6.
CBL
expression RUNX2
7.
CBX5
expression RUNX2
8.
CEBPA
expression RUNX2
9.
CEBPB
expression RUNX2
10.
CEBPB
protein-protein interactions ESR1
11.
CEBPB
protein-protein interactions RUNX2
12.
CREBBP
expression RUNX2
13.
CREBBP
protein-protein interactions AFP
14.
CREBBP
protein-protein interactions RUNX2
15.
CTNNB1
expression RUNX2
16.
CTNNB1
inhibition RUNX2
17.
CTNNB1
protein-DNA interactions RUNX2
18.
CTNNB1
protein-protein interactions RUNX2
19.
CTNNB1
transcription RUNX2
20.
DDX5
protein-protein interactions ESR1
21.
EED
expression RUNX2
22.
EED
modification RUNX2
23.
ELK1
expression RUNX2
24.
ELK1
protein-DNA interactions RUNX2
25.
EP300
expression RUNX2
26.
EP300
protein-protein interactions ESR1
27.
EP300
protein-protein interactions RUNX2
28.
ER/estrogen
membership ESR1
29.
ERBB2
activation CTNNB1
30.
ERBB2
activation EP300
31.
ERBB2
activation ERK1/2
32.
ERBB2
activation NOTCH1
33.
ERBB2
activation SP1
34.
ERBB2
activation STAT1
35.
ERBB2
activation STAT3
36.
ERBB2
activation histone H3
37.
ERBB2
inhibition FOXO3
38.
ERBB2
inhibition RB
39.
ERBB2
inhibition RB1
40.
ERBB2
phosphorylation CTNNB1
41.
ERBB2
phosphorylation EP300
42.
ERBB2
phosphorylation ERK1/2
43.
ERBB2
phosphorylation FOXO3
44.
ERBB2
phosphorylation RB
45.
ERBB2
phosphorylation RB1
46.
ERBB2
phosphorylation SP1
47.
ERBB2
phosphorylation STAT1
48.
ERBB2
phosphorylation STAT3
49.
ERBB2
phosphorylation histone H3
50.
ERBB2
protein-protein interactions CBL
51.
ERBB2
protein-protein interactions CCNB1
52.
ERBB2
protein-protein interactions CTNNB1
53.
ERBB2
protein-protein interactions CUL4A
54.
ERBB2
protein-protein interactions NOTCH1
55.
ERBB2
protein-protein interactions STAT1
56.
ERBB2
protein-protein interactions STAT3
57.
ERK1/2
activation RUNX2
58.
ERK1/2
protein-protein interactions RUNX2
59.
ESR1
RNA-RNA interactions: non-targeting interactions ESR2
60.
ESR1
activation Ap1
61.
ESR1
activation ESR2
62.
ESR1
activation RELA
63.
ESR1
activation RUNX2
64.
ESR1
activation SMAD3
65.
ESR1
activation SP1
66.
ESR1
activation STAT5A
67.
ESR1
activation TP53
68.
ESR1
chemical-protein interactions estrogen
69.
ESR1
expression AR
70.
ESR1
expression CBL
71.
ESR1
expression CCNB1
72.
ESR1
expression CEBPA
73.
ESR1
expression CEBPB
74.
ESR1
expression CEBPD
75.
ESR1
expression CTNNB1
76.
ESR1
expression CUL4B
77.
ESR1
expression EHMT2
78.
ESR1
expression EP300
79.
ESR1
expression ESR2
80.
ESR1
expression FOS
81.
ESR1
expression FOSB
82.
ESR1
expression FOSL1
83.
ESR1
expression FOSL2
84.
ESR1
expression FOXO1
85.
ESR1
expression FOXO4
86.
ESR1
expression GATA3
87.
ESR1
expression GLI2
88.
ESR1
expression GSN
89.
ESR1
expression HES1
90.
ESR1
expression HEY1
91.
ESR1
expression HIF1A
92.
ESR1
expression HSPD1
93.
ESR1
expression HSPH1
94.
ESR1
expression ID1
95.
ESR1
expression IRF4
96.
ESR1
expression JUN
97.
ESR1
expression JUNB
98.
ESR1
expression JUND
99.
ESR1
expression LIMA1
100.
ESR1
expression NFYB
101.
ESR1
expression NOTCH1
102.
ESR1
expression NR0B2
103.
ESR1
expression OSTF1
104.
ESR1
expression PPARD
105.
ESR1
expression PPARG
106.
ESR1
expression RB1
107.
ESR1
expression RBL2
108.
ESR1
expression RELA
109.
ESR1
expression RUNX2
110.
ESR1
expression SKP2
111.
ESR1
expression SMAD2
112.
ESR1
expression SMAD3
113.
ESR1
expression SMAD5
114.
ESR1
expression SMAD6
115.
ESR1
expression SMURF1
116.
ESR1
expression SMURF2
117.
ESR1
expression SNAI1
118.
ESR1
expression SNAI2
119.
ESR1
expression SOX9
120.
ESR1
expression SP1
121.
ESR1
expression STAT1
122.
ESR1
expression STAT3
123.
ESR1
expression STAT5A
124.
ESR1
expression TCF7L2
125.
ESR1
expression THRB
126.
ESR1
expression TP53
127.
ESR1
expression TRIB3
128.
ESR1
expression TSC22D3
129.
ESR1
expression VDR
130.
ESR1
expression ZBTB7B
131.
ESR1
inhibition RELA
132.
ESR1
inhibition RUNX2
133.
ESR1
inhibition TP53
134.
ESR1
protein-DNA interactions CREBBP
135.
ESR1
protein-DNA interactions ESRRA
136.
ESR1
protein-DNA interactions FOSL1
137.
ESR1
protein-DNA interactions FOXC1
138.
ESR1
protein-DNA interactions GATA3
139.
ESR1
protein-DNA interactions KAT6B
140.
ESR1
protein-DNA interactions NR0B2
141.
ESR1
protein-DNA interactions PPARGC1A
142.
ESR1
protein-DNA interactions SIRT1
143.
ESR1
protein-DNA interactions SOX9
144.
ESR1
protein-DNA interactions STAT5A
145.
ESR1
protein-DNA interactions TP53
146.
ESR1
protein-DNA interactions ZMYND8
147.
ESR1
protein-protein interactions ALYREF
148.
ESR1
protein-protein interactions AR
149.
ESR1
protein-protein interactions Ap1
150.
ESR1
protein-protein interactions CBX5
151.
ESR1
protein-protein interactions CEBPA
152.
ESR1
protein-protein interactions CEBPB
153.
ESR1
protein-protein interactions CIC
154.
ESR1
protein-protein interactions CREBBP
155.
ESR1
protein-protein interactions CTBP2
156.
ESR1
protein-protein interactions CTNNB1
157.
ESR1
protein-protein interactions CUL4B
158.
ESR1
protein-protein interactions DDX5
159.
ESR1
protein-protein interactions EHMT2
160.
ESR1
protein-protein interactions EP300
161.
ESR1
protein-protein interactions ERBB2
162.
ESR1
protein-protein interactions ESR2
163.
ESR1
protein-protein interactions ESRRA
164.
ESR1
protein-protein interactions FOS
165.
ESR1
protein-protein interactions FOSL2
166.
ESR1
protein-protein interactions FOXO1
167.
ESR1
protein-protein interactions FOXO4
168.
ESR1
protein-protein interactions GATA3
169.
ESR1
protein-protein interactions GSN
170.
ESR1
protein-protein interactions HDAC1
171.
ESR1
protein-protein interactions HIF1A
172.
ESR1
protein-protein interactions HSPD1
173.
ESR1
protein-protein interactions HSPH1
174.
ESR1
protein-protein interactions JUN
175.
ESR1
protein-protein interactions JUNB
176.
ESR1
protein-protein interactions JUND
177.
ESR1
protein-protein interactions LIMA1
178.
ESR1
protein-protein interactions NR0B2
179.
ESR1
protein-protein interactions PPARG
180.
ESR1
protein-protein interactions PPARGC1A
181.
ESR1
protein-protein interactions RELA
182.
ESR1
protein-protein interactions RUNX2
183.
ESR1
protein-protein interactions SIRT1
184.
ESR1
protein-protein interactions SKP2
185.
ESR1
protein-protein interactions SMAD2
186.
ESR1
protein-protein interactions SMAD3
187.
ESR1
protein-protein interactions SMURF1
188.
ESR1
protein-protein interactions SP1
189.
ESR1
protein-protein interactions STAT1
190.
ESR1
protein-protein interactions STAT3
191.
ESR1
protein-protein interactions STAT5A
192.
ESR1
protein-protein interactions TCF7L2
193.
ESR1
protein-protein interactions TP53
194.
ESR1
protein-protein interactions ZBTB7B
195.
ESR1
protein-protein interactions ZMYND8
196.
ESR1
transcription ESRRA
197.
ESR1
transcription FOS
198.
ESR1
transcription PPARGC1A
199.
ESR1
transcription RUNX2
200.
ESR1
transcription SIRT1
201.
ESR1
transcription TP53
202.
ESR2
RNA-RNA interactions: non-targeting interactions ESR1
203.
ESR2
activation AR
204.
ESR2
activation ESR1
205.
ESR2
activation RELA
206.
ESR2
activation SP1
207.
ESR2
activation STAT3
208.
ESR2
activation STAT5A
209.
ESR2
chemical-protein interactions estrogen
210.
ESR2
expression AR
211.
ESR2
expression CEBPD
212.
ESR2
expression CREBBP
213.
ESR2
expression CTNNB1
214.
ESR2
expression EHMT2
215.
ESR2
expression ELK1
216.
ESR2
expression EP300
217.
ESR2
expression ESR1
218.
ESR2
expression EZH2
219.
ESR2
expression FOS
220.
ESR2
expression FOSL2
221.
ESR2
expression FOXC2
222.
ESR2
expression FOXO1
223.
ESR2
expression FOXO3
224.
ESR2
expression GATA1
225.
ESR2
expression GATA3
226.
ESR2
expression HSPD1
227.
ESR2
expression JAG2
228.
ESR2
expression JUNB
229.
ESR2
expression KLF4
230.
ESR2
expression NOTCH1
231.
ESR2
expression RELA
232.
ESR2
expression RUNX2
233.
ESR2
expression SKP2
234.
ESR2
expression SMAD2
235.
ESR2
expression SMAD3
236.
ESR2
expression SMAD4
237.
ESR2
expression SNAI1
238.
ESR2
expression SNAI2
239.
ESR2
expression SP1
240.
ESR2
expression SRF
241.
ESR2
expression TWIST1
242.
ESR2
expression YY1
243.
ESR2
expression osteocalcin
244.
ESR2
inhibition RELA
245.
ESR2
protein-DNA interactions FOS
246.
ESR2
protein-RNA interactions CTNNB1
247.
ESR2
protein-protein interactions ALYREF
248.
ESR2
protein-protein interactions AR
249.
ESR2
protein-protein interactions ASAH1
250.
ESR2
protein-protein interactions CIC
251.
ESR2
protein-protein interactions CREBBP
252.
ESR2
protein-protein interactions CTBP2
253.
ESR2
protein-protein interactions CTNNB1
254.
ESR2
protein-protein interactions EED
255.
ESR2
protein-protein interactions EHMT2
256.
ESR2
protein-protein interactions EP300
257.
ESR2
protein-protein interactions ESR1
258.
ESR2
protein-protein interactions FOS
259.
ESR2
protein-protein interactions FOXO3
260.
ESR2
protein-protein interactions HSPD1
261.
ESR2
protein-protein interactions SMAD3
262.
ESR2
protein-protein interactions SMAD4
263.
ESR2
protein-protein interactions SP1
264.
ESR2
protein-protein interactions STAT3
265.
ESR2
protein-protein interactions STAT5A
266.
ESRRA
protein-DNA interactions RUNX2
267.
ESRRA
protein-protein interactions ESR1
268.
ESRRA
transcription RUNX2
269.
ESTG:ESR1:chaperone
membership ESR1
270.
ESTG:ESR2:chaperone
membership ESR2
271.
ESTG:Me-PalmS-ESR dimers
membership ESR1
272.
ESTG:Me-PalmS-ESR dimers
membership ESR2
273.
ETS1
protein-DNA interactions RUNX2
274.
ETS1
protein-protein interactions ESR1
275.
ETS1
protein-protein interactions RUNX2
276.
ETS1
transcription RUNX2
277.
EWSR1
protein-protein interactions ESR1
278.
EZH2
expression RUNX2
279.
EZH2
protein-protein interactions ESR1
280.
FHL2
protein-protein interactions ESR1
281.
FHL2
protein-protein interactions ESR2
282.
FKBP4
activation AR
283.
FKBP4
chemical-protein interactions estrogen
284.
FKBP4
protein-protein interactions AR
285.
FKBP4
protein-protein interactions CTNNB1
286.
FKBP4
protein-protein interactions DET1
287.
FKBP4
protein-protein interactions ESR1
288.
FKBP4
protein-protein interactions EWSR1
289.
FKBP4
protein-protein interactions EZH2
290.
FKBP4
protein-protein interactions NR3C1
291.
FOS
protein-DNA interactions RUNX2
292.
FOS
protein-protein interactions ESR1
293.
FOS
protein-protein interactions ESR2
294.
FOS
protein-protein interactions RUNX2
295.
FOS
protein-protein interactions estrogen receptor
296.
FOSB
protein-DNA interactions RUNX2
297.
FOSL1
protein-DNA interactions RUNX2
298.
FOSL2
protein-DNA interactions RUNX2
299.
FOSL2
protein-protein interactions ESR1
300.
FOXC1
expression RUNX2
301.
FOXC2
expression RUNX2
302.
FOXO1
activation RUNX2
303.
FOXO1
expression RUNX2
304.
FOXO1
protein-protein interactions ESR1
305.
FOXO1
protein-protein interactions RUNX2
306.
FOXO1
protein-protein interactions estrogen receptor
307.
FOXO3
expression RUNX2
308.
FOXO3
protein-protein interactions ESR1
309.
FOXO3
protein-protein interactions ESR2
310.
FOXO3
protein-protein interactions FKBP4
311.
FOXO4
expression RUNX2
312.
FOXO4
protein-protein interactions ESR1
313.
GATA1
expression RUNX2
314.
GATA3
protein-DNA interactions ESR1
315.
GATA3
protein-protein interactions ESR1
316.
GLI2
protein-protein interactions RUNX2
317.
GLI2
transcription RUNX2
318.
GNB2
protein-protein interactions ESR1
319.
GNB2
protein-protein interactions ESR2
320.
GNB2
protein-protein interactions FKBP4
321.
GPER1:Heterotrimeric G-protein Gs:ESTG
membership GNB2
322.
GSN
protein-protein interactions ERBB2
323.
GSN
protein-protein interactions ESR1
324.
GSN
protein-protein interactions ESR2
325.
HDAC1
protein-protein interactions ESR1
326.
HDAC1
protein-protein interactions ESR2
327.
HDAC3
activation RUNX2
328.
HDAC3
protein-protein interactions ESR1
329.
HDAC3
protein-protein interactions ESR2
330.
HDAC3
protein-protein interactions RUNX2
331.
HDAC4
activation RUNX2
332.
HDAC4
expression RUNX2
333.
HDAC4
protein-protein interactions ESR1
334.
HDAC4
protein-protein interactions RUNX2
335.
HDAC5
expression RUNX2
336.
HDAC5
protein-protein interactions ESR1
337.
HDAC5
protein-protein interactions RUNX2
338.
HDAC6
protein-protein interactions ERBB2
339.
HDAC6
protein-protein interactions ESR2
340.
HDAC7
protein-protein interactions ESR1
341.
HES1
activation RUNX2
342.
HES1
protein-protein interactions RUNX2
343.
HIF1A
protein-protein interactions ESR1
344.
HMGB2
expression RUNX2
345.
HMGB2
protein-DNA interactions RUNX2
346.
HMGB2
protein-protein interactions ESR1
347.
HMGB2
protein-protein interactions RUNX2
348.
HMGB2
protein-protein interactions estrogen receptor
349.
HMGB2
transcription RUNX2
350.
HSP90 (family)
activation AR
351.
HSP90 (family)
activation STAT3
352.
HSP90 (family)
activation TP53
353.
HSP90 (family)
chemical-protein interactions estrogen
354.
HSP90 (family)
protein-protein interactions AR
355.
HSP90 (family)
protein-protein interactions ESR1
356.
HSP90 (family)
protein-protein interactions EWSR1
357.
HSP90 (family)
protein-protein interactions GATA3
358.
HSP90 (family)
protein-protein interactions HDAC1
359.
HSP90 (family)
protein-protein interactions HDAC6
360.
HSP90 (family)
protein-protein interactions HIF1A
361.
HSP90 (family)
protein-protein interactions NR3C1
362.
HSP90 (family)
protein-protein interactions STAT3
363.
HSP90 (family)
protein-protein interactions STUB1
364.
HSP90 (family)
protein-protein interactions TP53
365.
HSP90 (family)
protein-protein interactions histone H4
366.
HSPA4
protein-protein interactions ERBB2
367.
HSPA4
protein-protein interactions ESR1
368.
HSPA4
protein-protein interactions ESR2
369.
HSPA4
protein-protein interactions FKBP4
370.
HSPA4L
protein-protein interactions ERBB2
371.
HSPA4L
protein-protein interactions ESR1
372.
HSPD1
protein-protein interactions ERBB2
373.
HSPD1
protein-protein interactions ESR1
374.
HSPD1
protein-protein interactions ESR2
375.
HSPH1
protein-protein interactions ESR1
376.
HSPH1
protein-protein interactions ESR2
377.
HSPH1
protein-protein interactions HSP90 (family)
378.
ID1
expression RUNX2
379.
IFI16
activation RUNX2
380.
IFI16
protein-protein interactions FKBP4
381.
IFI16
protein-protein interactions RUNX2
382.
IGF1
activation ESR1
383.
IGF1
activation TP53
384.
IGF1
chemical-protein interactions estrogen
385.
IMPDH1
protein-protein interactions ESR1
386.
IRF4
expression RUNX2
387.
IRF4
protein-protein interactions FKBP4
388.
JUN
protein-DNA interactions RUNX2
389.
JUN
protein-protein interactions ESR1
390.
JUN
protein-protein interactions ESR2
391.
JUN
protein-protein interactions RUNX2
392.
JUN
protein-protein interactions estrogen receptor
393.
JUNB
expression RUNX2
394.
JUNB
protein-protein interactions ESR1
395.
JUNB
protein-protein interactions RUNX2
396.
JUND
protein-DNA interactions RUNX2
397.
JUND
protein-protein interactions ESR1
398.
KAT2B
protein-protein interactions ESR1
399.
KAT2B
protein-protein interactions estrogen receptor
400.
KAT6A
expression RUNX2
401.
KAT6A
protein-protein interactions ESR1
402.
KAT6A
protein-protein interactions RUNX2
403.
KAT6B
protein-protein interactions ESR2
404.
KLF4
expression RUNX2
405.
KLF4
protein-DNA interactions RUNX2
406.
KLF4
protein-protein interactions ESR1
407.
KLF4
protein-protein interactions RUNX2
408.
LEF1
expression RUNX2
409.
LEF1
inhibition RUNX2
410.
LEF1
protein-DNA interactions RUNX2
411.
LEF1
protein-protein interactions ESR1
412.
LEF1
protein-protein interactions RUNX2
413.
LIMA1
protein-protein interactions ESR1
414.
LIMA1
protein-protein interactions HSP90 (family)
415.
MAP2K1
activation RUNX2
416.
MAP2K1
phosphorylation RUNX2
417.
MAP2K1
protein-protein interactions ERBB2
418.
MAP2K1
protein-protein interactions HSP90 (family)
419.
MATK
protein-protein interactions ERBB2
420.
MEN1
expression RUNX2
421.
MEN1
protein-protein interactions ESR1
422.
MEN1
protein-protein interactions ESR2
423.
MEN1
protein-protein interactions RUNX2
424.
MEN1
protein-protein interactions estrogen receptor
425.
MSX2
activation RUNX2
426.
MSX2
protein-protein interactions ESR1
427.
MSX2
protein-protein interactions RUNX2
428.
NFYB
protein-DNA interactions RUNX2
429.
NFYB
protein-protein interactions RUNX2
430.
NOTCH1
activation RUNX2
431.
NOTCH1
expression RUNX2
432.
NOTCH1
protein-protein interactions ERBB2
433.
NOTCH1
protein-protein interactions RUNX2
434.
NR0B2
protein-protein interactions ESR1
435.
NR0B2
protein-protein interactions ESR2
436.
NR0B2
protein-protein interactions estrogen receptor
437.
NR3C1
protein-DNA interactions RUNX2
438.
NR3C1
protein-protein interactions ESR1
439.
NR3C1
protein-protein interactions FKBP4
440.
NR3C1
protein-protein interactions HSP90 (family)
441.
NR3C1
protein-protein interactions estrogen receptor
442.
OSTF1
protein-DNA interactions RUNX2
443.
PIN1
activation RUNX2
444.
PIN1
protein-protein interactions ERBB2
445.
PIN1
protein-protein interactions ESR1
446.
PIN1
protein-protein interactions RUNX2
447.
PML
protein-protein interactions ESR2
448.
PPARD
expression RUNX2
449.
PPARD
protein-protein interactions HSP90 (family)
450.
PPARG
expression RUNX2
451.
PPARG
protein-protein interactions ESR1
452.
PPARG
protein-protein interactions HSP90 (family)
453.
PPARG
protein-protein interactions RUNX2
454.
PPARGC1A
protein-protein interactions ESR1
455.
PPARGC1A
protein-protein interactions ESR2
456.
PPARGC1A
transcription RUNX2
457.
PPARGC1B
protein-protein interactions ESR1
458.
PPARGC1B
transcription RUNX2
459.
PTH
chemical-protein interactions estrogen
460.
RB
activation RUNX2
461.
RB
protein-protein interactions RUNX2
462.
RB1
protein-protein interactions ESR2
463.
RB1
protein-protein interactions estrogen receptor
464.
RBM14
protein-protein interactions ERBB2
465.
RBM14
protein-protein interactions ESR1
466.
RBM28
protein-protein interactions ESR1
467.
RELA
expression RUNX2
468.
RELA
protein-protein interactions ESR1
469.
RUNX1
expression RUNX2
470.
RUNX1
protein-DNA interactions RUNX2
471.
RUNX1
protein-protein interactions ESR1
472.
RUNX1
protein-protein interactions RUNX2
473.
RUNX2
activation NOTCH1
474.
RUNX2
activation RUNX2
475.
RUNX2
expression RUNX2
476.
RUNX2
inhibition RUNX2
477.
RUNX2
localization RUNX2
478.
RUNX2
modification RUNX2
479.
RUNX2
molecular cleavage RUNX2
480.
RUNX2
protein-DNA interactions RUNX2
481.
RUNX2
protein-protein interactions ALYREF
482.
RUNX2
protein-protein interactions AR
483.
RUNX2
protein-protein interactions Ap1
484.
RUNX2
protein-protein interactions CCNB1
485.
RUNX2
protein-protein interactions CEBPB
486.
RUNX2
protein-protein interactions CEBPD
487.
RUNX2
protein-protein interactions CIC
488.
RUNX2
protein-protein interactions CREBBP
489.
RUNX2
protein-protein interactions CTBP2
490.
RUNX2
protein-protein interactions CTNNB1
491.
RUNX2
protein-protein interactions CUL4A
492.
RUNX2
protein-protein interactions CUL4B
493.
RUNX2
protein-protein interactions DDX5
494.
RUNX2
protein-protein interactions DET1
495.
RUNX2
protein-protein interactions EHMT2
496.
RUNX2
protein-protein interactions EP300
497.
RUNX2
protein-protein interactions ERK1/2
498.
RUNX2
protein-protein interactions ESR1
499.
RUNX2
protein-protein interactions ETS1
500.
RUNX2
protein-protein interactions EWSR1
501.
RUNX2
protein-protein interactions FHL2
502.
RUNX2
protein-protein interactions FOS
503.
RUNX2
protein-protein interactions FOXO1
504.
RUNX2
protein-protein interactions GATA3
505.
RUNX2
protein-protein interactions GLI2
506.
RUNX2
protein-protein interactions GNB2
507.
RUNX2
protein-protein interactions GSN
508.
RUNX2
protein-protein interactions HDAC1
509.
RUNX2
protein-protein interactions HDAC3
510.
RUNX2
protein-protein interactions HDAC4
511.
RUNX2
protein-protein interactions HDAC5
512.
RUNX2
protein-protein interactions HDAC6
513.
RUNX2
protein-protein interactions HDAC7
514.
RUNX2
protein-protein interactions HES1
515.
RUNX2
protein-protein interactions HEY1
516.
RUNX2
protein-protein interactions HIF1A
517.
RUNX2
protein-protein interactions HMGB2
518.
RUNX2
protein-protein interactions HSPA4
519.
RUNX2
protein-protein interactions HSPA4L
520.
RUNX2
protein-protein interactions HSPD1
521.
RUNX2
protein-protein interactions HSPH1
522.
RUNX2
protein-protein interactions IFI16
523.
RUNX2
protein-protein interactions IMPDH1
524.
RUNX2
protein-protein interactions JAG2
525.
RUNX2
protein-protein interactions JUN
526.
RUNX2
protein-protein interactions JUNB
527.
RUNX2
protein-protein interactions KAT2B
528.
RUNX2
protein-protein interactions KAT6A
529.
RUNX2
protein-protein interactions KAT6B
530.
RUNX2
protein-protein interactions KLF4
531.
RUNX2
protein-protein interactions LEF1
532.
RUNX2
protein-protein interactions LIMA1
533.
RUNX2
protein-protein interactions MATK
534.
RUNX2
protein-protein interactions MEN1
535.
RUNX2
protein-protein interactions MSX2
536.
RUNX2
protein-protein interactions NFYB
537.
RUNX2
protein-protein interactions NOTCH1
538.
RUNX2
protein-protein interactions NR0B2
539.
RUNX2
protein-protein interactions PIN1
540.
RUNX2
protein-protein interactions PML
541.
RUNX2
protein-protein interactions PPARG
542.
RUNX2
protein-protein interactions RB
543.
RUNX2
protein-protein interactions RB1
544.
RUNX2
protein-protein interactions RBL2
545.
RUNX2
protein-protein interactions RBM14
546.
RUNX2
protein-protein interactions RBM28
547.
RUNX2
protein-protein interactions RUNX1
548.
RUNX2
protein-protein interactions SMAD4
549.
RUNX2
protein-protein interactions SMAD5
550.
RUNX2
protein-protein interactions SNAI1
551.
RUNX2
protein-protein interactions osteocalcin
552.
RUNX2
regulation of binding RUNX2
553.
RUNX2
ubiquitination RUNX2
554.
SIRT1
expression RUNX2
555.
SIRT1
protein-protein interactions AFP
556.
SIRT1
protein-protein interactions ESR1
557.
SIRT1
protein-protein interactions RUNX2
558.
SKIC2
protein-protein interactions ESR1
559.
SKIC2
protein-protein interactions ESR2
560.
SKIC2
protein-protein interactions RUNX2
561.
SKP2
protein-protein interactions ESR1
562.
SKP2
protein-protein interactions FKBP4
563.
SKP2
protein-protein interactions RUNX2
564.
SMAD1
expression RUNX2
565.
SMAD1
protein-protein interactions ERBB2
566.
SMAD1
protein-protein interactions ESR1
567.
SMAD1
protein-protein interactions RUNX2
568.
SMAD2
expression RUNX2
569.
SMAD2
protein-protein interactions ESR1
570.
SMAD2
protein-protein interactions RUNX2
571.
SMAD2
protein-protein interactions estrogen receptor
572.
SMAD3
expression RUNX2
573.
SMAD3
protein-protein interactions ESR1
574.
SMAD3
protein-protein interactions ESR2
575.
SMAD3
protein-protein interactions RUNX2
576.
SMAD3
protein-protein interactions estrogen receptor
577.
SMAD4
expression RUNX2
578.
SMAD4
protein-DNA interactions RUNX2
579.
SMAD4
protein-protein interactions ESR1
580.
SMAD4
protein-protein interactions ESR2
581.
SMAD4
protein-protein interactions RUNX2
582.
SMAD4
protein-protein interactions estrogen receptor
583.
SMAD5
expression RUNX2
584.
SMAD5
protein-protein interactions RUNX2
585.
SMAD6
inhibition RUNX2
586.
SMAD6
protein-protein interactions RUNX2
587.
SMARCA4
expression RUNX2
588.
SMARCA4
protein-DNA interactions RUNX2
589.
SMARCA4
protein-protein interactions ESR1
590.
SMARCA4
protein-protein interactions ESR2
591.
SMARCA4
protein-protein interactions RUNX2
592.
SMARCA4
protein-protein interactions estrogen receptor
593.
SMURF1
inhibition RUNX2
594.
SMURF1
protein-protein interactions ESR1
595.
SMURF1
protein-protein interactions RUNX2
596.
SMURF1
ubiquitination RUNX2
597.
SMURF2
protein-protein interactions ERBB2
598.
SMURF2
protein-protein interactions FKBP4
599.
SMURF2
protein-protein interactions RUNX2
600.
SNAI1
protein-protein interactions RUNX2
601.
SNAI1
transcription RUNX2
602.
SNAI2
activation RUNX2
603.
SNAI2
transcription RUNX2
604.
SOX2
protein-protein interactions FKBP4
605.
SOX2
protein-protein interactions HSP90 (family)
606.
SOX2
protein-protein interactions RUNX2
607.
SOX9
expression RUNX2
608.
SOX9
protein-protein interactions RUNX2
609.
SP1
expression ESR1
610.
SP1
expression RUNX2
611.
SP1
protein-DNA interactions RUNX2
612.
SP1
protein-protein interactions ESR1
613.
SP1
protein-protein interactions ESR2
614.
SP1
protein-protein interactions estrogen receptor
615.
SP1
transcription RUNX2
616.
SRF
activation RUNX2
617.
SRF
protein-protein interactions RUNX2
618.
STAT1
inhibition RUNX2
619.
STAT1
protein-protein interactions ERBB2
620.
STAT1
protein-protein interactions ESR1
621.
STAT1
protein-protein interactions ESR2
622.
STAT1
protein-protein interactions RUNX2
623.
STAT3
protein-protein interactions ERBB2
624.
STAT3
protein-protein interactions ESR1
625.
STAT3
protein-protein interactions ESR2
626.
STAT3
protein-protein interactions HSP90 (family)
627.
STAT3
protein-protein interactions RUNX2
628.
STAT5A
expression RUNX2
629.
STAT5A
protein-protein interactions ESR1
630.
STAT5A
protein-protein interactions ESR2
631.
STAT5A
protein-protein interactions RUNX2
632.
STUB1
protein-protein interactions ERBB2
633.
STUB1
protein-protein interactions ESR1
634.
STUB1
protein-protein interactions ESR2
635.
STUB1
protein-protein interactions HSP90 (family)
636.
STUB1
protein-protein interactions RUNX2
637.
SUV39H1
protein-protein interactions ESR1
638.
SUV39H1
protein-protein interactions RUNX2
639.
TAF1A
protein-protein interactions ESR1
640.
TAF1A
protein-protein interactions RUNX2
641.
TCF7L2
protein-protein interactions ESR1
642.
TCF7L2
protein-protein interactions ESR2
643.
TCF7L2
protein-protein interactions RUNX2
644.
TFAM
expression RUNX2
645.
TFAM
protein-protein interactions ESR1
646.
THRAP3
expression RUNX2
647.
THRAP3
protein-protein interactions ESR1
648.
THRB
expression RUNX2
649.
THRB
protein-DNA interactions RUNX2
650.
THRB
protein-protein interactions estrogen receptor
651.
THRB
transcription RUNX2
652.
TLE1
activation RUNX2
653.
TLE1
protein-protein interactions ESR1
654.
TLE1
protein-protein interactions RUNX2
655.
TP53
expression ESR1
656.
TP53
expression RUNX2
657.
TP53
protein-protein interactions ESR1
658.
TP53
protein-protein interactions ESR2
659.
TP53
protein-protein interactions FKBP4
660.
TP53
protein-protein interactions HSP90 (family)
661.
TP53
protein-protein interactions PTH
662.
TP53
protein-protein interactions RUNX2
663.
TP53
transcription RUNX2
664.
TP73
protein-protein interactions HSP90 (family)
665.
TP73
protein-protein interactions RUNX2
666.
TRIB3
expression RUNX2
667.
TRPS1
expression RUNX2
668.
TRPS1
protein-protein interactions ESR1
669.
TSC22D3
expression RUNX2
670.
TWIST1
expression RUNX2
671.
TWIST1
protein-protein interactions RUNX2
672.
UBTF
protein-protein interactions ESR1
673.
UBTF
protein-protein interactions RUNX2
674.
VDR
expression RUNX2
675.
VDR
protein-protein interactions HSP90 (family)
676.
VDR
protein-protein interactions RUNX2
677.
WDR5
expression RUNX2
678.
WDR5
protein-DNA interactions RUNX2
679.
WDR5
protein-protein interactions ESR1
680.
WDR5
protein-protein interactions ESR2
681.
WWP1
protein-protein interactions ESR2
682.
WWP1
protein-protein interactions RUNX2
683.
WWP1
ubiquitination RUNX2
684.
WWP2
protein-protein interactions ERBB2
685.
WWP2
protein-protein interactions RUNX2
686.
XRCC5
protein-protein interactions ESR1
687.
XRCC5
protein-protein interactions ESR2
688.
XRCC5
protein-protein interactions RUNX2
689.
XRCC6
protein-protein interactions ESR1
690.
XRCC6
protein-protein interactions RUNX2
691.
YAP1
expression RUNX2
692.
YAP1
protein-protein interactions ESR2
693.
YAP1
protein-protein interactions RUNX2
694.
YY1
activation RUNX2
695.
YY1
protein-protein interactions RUNX2
696.
ZBTB16
expression RUNX2
697.
ZBTB16
protein-protein interactions ESR1
698.
ZBTB7B
protein-protein interactions ESR1
699.
ZBTB7B
protein-protein interactions ESR2
700.
ZBTB7B
protein-protein interactions RUNX2
701.
ZMYND8
expression RUNX2
702.
ZMYND8
protein-protein interactions ERBB2
703.
ZMYND8
protein-protein interactions ESR1
704.
ZMYND8
protein-protein interactions ESR2
705.
estrogen
activation ERBB2
706.
estrogen
activation ESR1
707.
estrogen
activation ESR2
708.
estrogen
activation RUNX2
709.
estrogen
activation estrogen receptor
710.
estrogen
chemical-protein interactions AFP
711.
estrogen
chemical-protein interactions ERBB2
712.
estrogen
chemical-protein interactions ESR1
713.
estrogen
chemical-protein interactions ESR2
714.
estrogen
chemical-protein interactions estrogen receptor
715.
estrogen
inhibition ERBB2
716.
estrogen
reaction ER/estrogen
717.
estrogen
reaction ESTG:ESR1:chaperone
718.
estrogen
reaction ESTG:ESR2:chaperone
719.
estrogen
reaction ESTG:Me-PalmS-ESR dimers
720.
estrogen
translocation estrogen
721.
estrogen receptor
activation FOS
722.
estrogen receptor
activation JUN
723.
estrogen receptor
activation TP53
724.
estrogen receptor
chemical-protein interactions estrogen
725.
estrogen receptor
inhibition DDX5
726.
estrogen receptor
membership ESR1
727.
estrogen receptor
membership ESR2
728.
estrogen receptor
protein-DNA interactions FOS
729.
estrogen receptor
protein-protein interactions AR
730.
estrogen receptor
protein-protein interactions CREBBP
731.
estrogen receptor
protein-protein interactions DDX5
732.
estrogen receptor
protein-protein interactions EP300
733.
estrogen receptor
protein-protein interactions FOS
734.
estrogen receptor
protein-protein interactions JUN
735.
histone H3
protein-DNA interactions RUNX2
736.
histone H4
protein-DNA interactions RUNX2
Table 5. Various molecules incorporated in the miRNA-9 and RUNX-2 gene expression.
Table 5. Various molecules incorporated in the miRNA-9 and RUNX-2 gene expression.
Symbol Molecule/ Gene Name Location Family
  • AR
androgen receptor Nucleus ligand-dependent nuclear receptor
2.
CTNNB1
catenin beta 1 Nucleus transcription regulator
3.
CXCR4
C-X-C motif chemokine receptor 4 Plasma Membrane G-protein coupled receptor
4.
ELAVL1
ELAV like RNA binding protein 1 Cytoplasm other
5.
ETS1
ETS proto-oncogene 1, transcription factor Nucleus transcription regulator
6.
MEIS2
Meis homeobox 2 Nucleus transcription regulator
7.
mir-9 (includes others)
relatives of microRNA 9 Cytoplasm microRNA
8.
RUNX1
RUNX family transcription factor 1 Nucleus transcription regulator
9.
RUNX2
RUNX family transcription factor 2 Nucleus transcription regulator
10.
SP1
Sp1 transcription factor Nucleus transcription regulator
Table 6. Various interactions between molecules incorporated in the miRNA-9 and RUNX-2 gene expression.
Table 6. Various interactions between molecules incorporated in the miRNA-9 and RUNX-2 gene expression.
From Molecule(s) Relationship Type To Molecule(s)
  • CTNNB1
expression RUNX2
2.
CTNNB1
inhibition RUNX2
3.
CTNNB1
protein-DNA interactions RUNX2
4.
CTNNB1
protein-protein interactions RUNX2
5.
CTNNB1
transcription RUNX2
6.
CXCR4
expression RUNX2
7.
ELAVL1
expression RUNX2
8.
ETS1
protein-DNA interactions RUNX2
9.
ETS1
protein-protein interactions RUNX2
10.
ETS1
transcription RUNX2
11.
MEIS2
expression RUNX2
12.
RUNX1
expression RUNX2
13.
RUNX1
protein-DNA interactions RUNX2
14.
RUNX1
protein-protein interactions RUNX2
15.
RUNX2
activation RUNX2
16.
RUNX2
expression RUNX2
17.
RUNX2
inhibition RUNX2
18.
RUNX2
localization RUNX2
19.
RUNX2
modification RUNX2
20.
RUNX2
molecular cleavage RUNX2
21.
RUNX2
protein-DNA interactions RUNX2
22.
RUNX2
protein-protein interactions AR
23.
RUNX2
protein-protein interactions CTNNB1
24.
RUNX2
protein-protein interactions ETS1
25.
RUNX2
protein-protein interactions RUNX1
26.
RUNX2
regulation of binding RUNX2
27.
RUNX2
ubiquitination RUNX2
28.
SP1
expression RUNX2
29.
SP1
protein-DNA interactions RUNX2
30.
SP1
transcription RUNX2
31.
mir-9
RNA-RNA interactions: microRNA targeting AR
32.
mir-9
RNA-RNA interactions: microRNA targeting CXCR4
33.
mir-9
RNA-RNA interactions: microRNA targeting ETS1
34.
mir-9
RNA-RNA interactions: microRNA targeting RUNX1
35.
mir-9
RNA-RNA interactions: non-targeting interactions AR
36.
mir-9
expression AR
37.
mir-9
expression CTNNB1
38.
mir-9
expression CXCR4
39.
mir-9
expression ETS1
40.
mir-9
expression MEIS2
41.
mir-9
expression RUNX1
42.
mir-9
expression SP1
43.
mir-9
inhibition ELAVL1
Table 7. Various molecules incorporated in the regulation of miRNA-10 and affect RUNX-2 gene expression.
Table 7. Various molecules incorporated in the regulation of miRNA-10 and affect RUNX-2 gene expression.
Symbol Molecule/ Gene Name Location Family
  • AKT
Cytoplasm group
2.
AR
androgen receptor Nucleus ligand-dependent nuclear receptor
3.
BMPR2
bone morphogenetic protein receptor type 2 Plasma Membrane kinase
4.
CASP3
caspase 3 Cytoplasm peptidase
5.
E2F1
E2F transcription factor 1 Nucleus transcription regulator
6.
EGFR
epidermal growth factor receptor Plasma Membrane kinase
7.
ERK1/2
Cytoplasm group
8.
GLI1
GLI family zinc finger 1 Nucleus transcription regulator
9.
HDAC4
histone deacetylase 4 Nucleus transcription regulator
10.
HIF1A
hypoxia inducible factor 1 subunit alpha Nucleus transcription regulator
11.
histone H3
Nucleus Group
12.
hydrogen peroxide
Other chemical - endogenous mammalian
13.
IFNG
interferon gamma Extracellular Space Cytokine
14.
IGF1R
insulin like growth factor 1 receptor Plasma Membrane transmembrane receptor
15.
IL6
interleukin 6 Extracellular Space Cytokine
16.
IRF4
interferon regulatory factor 4 Nucleus transcription regulator
17.
JUN
Jun proto-oncogene, AP-1 transcription factor subunit Nucleus transcription regulator
18.
KLF4
KLF transcription factor 4 Nucleus transcription regulator
19.
mir-10 (includes others)
relatives of microRNA 10 Cytoplasm microRNA
20.
MTOR
mechanistic target of rapamycin kinase Nucleus Kinase
21.
MYD88
MYD88 innate immune signal transduction adaptor Plasma Membrane other
22.
NFE2L2
NFE2 like bZIP transcription factor 2 Nucleus transcription regulator
23.
p38 MAPK
Cytoplasm group
24.
PPP1CA
protein phosphatase 1 catalytic subunit alpha Cytoplasm phosphatase
25.
PTEN
phosphatase and tensin homolog Cytoplasm phosphatase
26.
RB1
RB transcriptional corepressor 1 Nucleus transcription regulator
27.
RUNX2
RUNX family transcription factor 2 Nucleus transcription regulator
28.
SMAD2
SMAD family member 2 Nucleus transcription regulator
29.
SMAD4
SMAD family member 4 Nucleus transcription regulator
30.
STAT3
signal transducer and activator of transcription 3 Nucleus transcription regulator
31.
SUV39H1
SUV39H1 histone lysine methyltransferase Nucleus enzyme
32.
TGF beta
Extracellular Space group
33.
TGFBR2
transforming growth factor beta receptor 2 Plasma Membrane kinase
34.
TNF
tumor necrosis factor Extracellular Space cytokine
35.
TP53
tumor protein p53 Nucleus transcription regulator
36.
VEGFA
vascular endothelial growth factor A Extracellular Space growth factor
Table 8. Various interactions between molecules incorporated in the miRNA-10 and RUNX-2 gene expression.
Table 8. Various interactions between molecules incorporated in the miRNA-10 and RUNX-2 gene expression.
From Molecule(s) Relationship Type To Molecule(s)
  • AKT
activation RUNX2
2.
AKT
expression RUNX2
3.
AKT
phosphorylation RUNX2
4.
BMPR2
expression RUNX2
5.
BMPR2
regulation of binding RUNX2
6.
CASP3
expression RUNX2
7.
E2F1
regulation of binding RUNX2
8.
EGFR
expression RUNX2
9.
ERK1/2
activation RUNX2
10.
ERK1/2
expression RUNX2
11.
ERK1/2
phosphorylation RUNX2
12.
ERK1/2
protein-protein interactions RUNX2
13.
GLI1
expression RUNX2
14.
GLI1
protein-protein interactions RUNX2
15.
GLI1
transcription RUNX2
16.
HDAC4
activation RUNX2
17.
HDAC4
expression RUNX2
18.
HDAC4
modification RUNX2
19.
HDAC4
protein-protein interactions RUNX2
20.
IFNG
expression RUNX2
21.
IGF1R
expression RUNX2
22.
IL6
expression RUNX2
23.
IRF4
expression RUNX2
24.
JUN
protein-DNA interactions RUNX2
25.
JUN
protein-protein interactions RUNX2
26.
KLF4
expression RUNX2
27.
KLF4
protein-DNA interactions RUNX2
28.
KLF4
protein-protein interactions RUNX2
29.
MTOR
expression RUNX2
30.
MYD88
expression RUNX2
31.
NFE2L2
protein-protein interactions RUNX2
32.
NFE2L2
regulation of binding RUNX2
33.
PPP1CA
expression RUNX2
34.
PTEN
regulation of binding RUNX2
35.
RUNX2
activation RUNX2
36.
RUNX2
expression RUNX2
37.
RUNX2
inhibition RUNX2
38.
RUNX2
localization RUNX2
39.
RUNX2
modification RUNX2
40.
RUNX2
molecular cleavage RUNX2
41.
RUNX2
protein-DNA interactions RUNX2
42.
RUNX2
protein-protein interactions AR
43.
RUNX2
protein-protein interactions ERK1/2
44.
RUNX2
protein-protein interactions GLI1
45.
RUNX2
protein-protein interactions HDAC4
46.
RUNX2
protein-protein interactions HIF1A
47.
RUNX2
protein-protein interactions JUN
48.
RUNX2
protein-protein interactions KLF4
49.
RUNX2
protein-protein interactions NFE2L2
50.
RUNX2
protein-protein interactions RB1
51.
RUNX2
protein-protein interactions SMAD4
52.
RUNX2
regulation of binding RUNX2
53.
RUNX2
ubiquitination RUNX2
54.
SMAD2
expression RUNX2
55.
SMAD2
protein-protein interactions RUNX2
56.
SMAD4
expression RUNX2
57.
SMAD4
protein-DNA interactions RUNX2
58.
SMAD4
protein-protein interactions RUNX2
59.
STAT3
expression RUNX2
60.
STAT3
protein-protein interactions RUNX2
61.
SUV39H1
protein-protein interactions RUNX2
62.
SUV39H1
protein-protein interactions mir-10 (includes others)
63.
TGF beta
expression RUNX2
64.
TGFBR2
expression RUNX2
65.
TNF
expression RUNX2
66.
TNF
localization RUNX2
67.
TNF
molecular cleavage RUNX2
68.
TNF
transcription RUNX2
69.
TP53
expression RUNX2
70.
TP53
protein-protein interactions RUNX2
71.
TP53
transcription RUNX2
72.
VEGFA
expression RUNX2
73.
histone H3
protein-DNA interactions RUNX2
74.
hydrogen peroxide
expression RUNX2
75.
mir-10 (includes others)
RNA-RNA interactions: microRNA targeting AR
76.
mir-10 (includes others)
RNA-RNA interactions: microRNA targeting BMPR2
77.
mir-10 (includes others)
RNA-RNA interactions: microRNA targeting HDAC4
78.
mir-10 (includes others)
RNA-RNA interactions: microRNA targeting IGF1R
79.
mir-10 (includes others)
RNA-RNA interactions: microRNA targeting KLF4
80.
mir-10 (includes others)
RNA-RNA interactions: microRNA targeting MTOR
81.
mir-10 (includes others)
RNA-RNA interactions: microRNA targeting MYD88
82.
mir-10 (includes others)
RNA-RNA interactions: microRNA targeting PPP1CA
83.
mir-10 (includes others)
RNA-RNA interactions: microRNA targeting PTEN
84.
mir-10 (includes others)
RNA-RNA interactions: microRNA targeting SMAD2
85.
mir-10 (includes others)
RNA-RNA interactions: microRNA targeting SMAD4
86.
mir-10 (includes others)
RNA-RNA interactions: microRNA targeting SUV39H1
87.
mir-10 (includes others)
RNA-RNA interactions: microRNA targeting TNF
88.
mir-10 (includes others)
RNA-RNA interactions: microRNA targeting TP53
89.
mir-10 (includes others)
RNA-RNA interactions: non-targeting interactions JUN
90.
mir-10 (includes others)
activation AKT
91.
mir-10 (includes others)
activation CASP3
92.
mir-10 (includes others)
activation EGFR
93.
mir-10 (includes others)
activation ERK1/2
94.
mir-10 (includes others)
activation STAT3
95.
mir-10 (includes others)
activation TP53
96.
mir-10 (includes others)
expression AKT
97.
mir-10 (includes others)
expression AR
98.
mir-10 (includes others)
expression BMPR2
99.
mir-10 (includes others)
expression E2F1
100.
mir-10 (includes others)
expression GLI1
101.
mir-10 (includes others)
expression HDAC4
102.
mir-10 (includes others)
expression HIF1A
103.
mir-10 (includes others)
expression IGF1R
104.
mir-10 (includes others)
expression IL6
105.
mir-10 (includes others)
expression IRF4
106.
mir-10 (includes others)
expression KLF4
107.
mir-10 (includes others)
expression MTOR
108.
mir-10 (includes others)
expression MYD88
109.
mir-10 (includes others)
expression NFE2L2
110.
mir-10 (includes others)
expression PPP1CA
111.
mir-10 (includes others)
expression PTEN
112.
mir-10 (includes others)
expression RB1
113.
mir-10 (includes others)
expression SMAD2
114.
mir-10 (includes others)
expression SMAD4
115.
mir-10 (includes others)
expression SUV39H1
116.
mir-10 (includes others)
expression TGF beta
117.
mir-10 (includes others)
expression TGFBR2
118.
mir-10 (includes others)
expression TNF
119.
mir-10 (includes others)
expression TP53
120.
mir-10 (includes others)
expression VEGFA
121.
mir-10 (includes others)
expression p38 MAPK
122.
mir-10 (includes others)
localization IFNG
123.
mir-10 (includes others)
localization hydrogen peroxide
124.
mir-10 (includes others)
molecular cleavage CASP3
125.
mir-10 (includes others)
phosphorylation AKT
126.
mir-10 (includes others)
phosphorylation EGFR
127.
mir-10 (includes others)
phosphorylation ERK1/2
128.
mir-10 (includes others)
phosphorylation STAT3
129.
mir-10 (includes others)
protein-protein interactions SUV39H1
130.
mir-10 (includes others)
regulation of binding IL6
131.
mir-10 (includes others)
regulation of binding histone H3
132.
mir-10 (includes others)
translocation STAT3
133.
p38 MAPK
activation RUNX2
134.
p38 MAPK
expression RUNX2
Table 9. Various molecules incorporated in the regulation of PDLIM-3 and affect miRNA9 expression.
Table 9. Various molecules incorporated in the regulation of PDLIM-3 and affect miRNA9 expression.
Symbol Molecule/ Gene Name Location Family
  • ACTN2
actinin alpha 2 Nucleus transcription regulator
2.
AGO2
argonaute RISC catalytic component 2 Cytoplasm translation regulator
3.
AGO3
argonaute RISC catalytic component 3 Cytoplasm translation regulator
4.
AGR2
anterior gradient 2, protein disulphide isomerase family member Extracellular Space other
5.
AR
androgen receptor Nucleus ligand-dependent nuclear receptor
6.
BAG3
BAG cochaperone 3 Cytoplasm other
7.
BICD1
BICD cargo adaptor 1 Cytoplasm other
8.
CD274
CD274 molecule Plasma Membrane transmembrane receptor
9.
CUL3
cullin 3 Nucleus enzyme
10.
DCTN1
dynactin subunit 1 Cytoplasm other
11.
DROSHA
drosha ribonuclease III Nucleus enzyme
12.
FHL1
four and a half LIM domains 1 Cytoplasm other
13.
FUS
FUS RNA binding protein Nucleus transcription regulator
14.
FXR1
FMR1 autosomal homolog 1 Cytoplasm other
15.
LMNA
lamin A/C Nucleus other
16.
mir-9
relatives of microRNA 9 Cytoplasm microRNA
17.
MYC
MYC proto-oncogene, bHLH transcription factor Nucleus transcription regulator
18.
MYCN
MYCN proto-oncogene, bHLH transcription factor Nucleus transcription regulator
19.
NAA40
N-alpha-acetyltransferase 40, NatD catalytic subunit Cytoplasm enzyme
20.
PALLD
palladin, cytoskeletal associated protein Plasma Membrane other
21.
PCNA
proliferating cell nuclear antigen Nucleus enzyme
22.
PDLIM3
PDZ and LIM domain 3 Cytoplasm other
23.
PMP22
peripheral myelin protein 22 Plasma Membrane other
24.
PRPH
peripherin Plasma Membrane other
25.
RANBP2
RAN binding protein 2 Nucleus enzyme
26.
REST
RE1 silencing transcription factor Nucleus transcription regulator
27.
SQSTM1
sequestosome 1 Cytoplasm transcription regulator
28.
TARDBP
TAR DNA binding protein Nucleus transcription regulator
29.
VIM
vimentin Cytoplasm other
30.
YAP1
Yes1 associated transcriptional regulator Nucleus transcription regulator
Table 10. Various interactions between molecules incorporated in the PDLIM-3 and affect miRNA9 expression.
Table 10. Various interactions between molecules incorporated in the PDLIM-3 and affect miRNA9 expression.
From Molecule(s) Relationship Type To Molecule(s)
  • ACTN2
activation AR
2.
ACTN2
protein-protein interactions AR
3.
AGR2
protein-protein interactions AGO2
4.
AR
protein-protein interactions ACTN2
5.
BAG3
expression MYC
6.
BAG3
protein-protein interactions MYC
7.
BICD1
protein-protein interactions AGO3
8.
CD274
expression mir-9 (includes others)
9.
CUL3
expression CD274
10.
CUL3
protein-protein interactions AGO2
11.
CUL3
protein-protein interactions AGO3
12.
CUL3
protein-protein interactions CD274
13.
DROSHA
protein-DNA interactions mir-9 (includes others)
14.
DROSHA
protein-protein interactions CUL3
15.
FUS
protein-RNA interactions mir-9 (includes others)
16.
FUS
protein-protein interactions AGR2
17.
FUS
protein-protein interactions CUL3
18.
FUS
regulation of binding mir-9 (includes others)
19.
FXR1
expression mir-9 (includes others)
20.
FXR1
molecular cleavage mir-9 (includes others)
21.
FXR1
protein-RNA interactions mir-9 (includes others)
22.
FXR1
protein-protein interactions ACTN2
23.
FXR1
protein-protein interactions BICD1
24.
FXR1
protein-protein interactions CUL3
25.
FXR1
protein-protein interactions DCTN1
26.
LMNA
expression MYC
27.
LMNA
inhibition YAP1
28.
LMNA
localization YAP1
29.
LMNA
phosphorylation YAP1
30.
LMNA
protein-protein interactions FUS
31.
LMNA
protein-protein interactions FXR1
32.
LMNA
protein-protein interactions MYC
33.
LMNA
protein-protein interactions YAP1
34.
LMNA
transcription YAP1
35.
MYC
expression mir-9 (includes others)
36.
MYC
protein-DNA interactions mir-9 (includes others)
37.
MYC
protein-protein interactions BAG3
38.
MYC
protein-protein interactions DCTN1
39.
MYC
protein-protein interactions LMNA
40.
MYC
transcription mir-9 (includes others)
41.
MYCN
protein-DNA interactions mir-9 (includes others)
42.
MYCN
protein-protein interactions CUL3
43.
MYCN
protein-protein interactions FHL1
44.
MYCN
protein-protein interactions LMNA
45.
PALLD
protein-protein interactions MYC
46.
PCNA
protein-protein interactions AR
47.
PCNA
protein-protein interactions FUS
48.
PCNA
protein-protein interactions MYC
49.
PCNA
protein-protein interactions MYCN
50.
PDLIM3
protein-protein interactions ACTN2
51.
PDLIM3
protein-protein interactions AGR2
52.
PDLIM3
protein-protein interactions BAG3
53.
PDLIM3
protein-protein interactions BICD1
54.
PDLIM3
protein-protein interactions CUL3
55.
PDLIM3
protein-protein interactions DCTN1
56.
PDLIM3
protein-protein interactions FHL1
57.
PDLIM3
protein-protein interactions LMNA
58.
PDLIM3
protein-protein interactions NAA40
59.
PDLIM3
protein-protein interactions PALLD
60.
PDLIM3
protein-protein interactions PCNA
61.
PDLIM3
regulation of binding ACTN2
62.
PMP22
RNA-RNA interactions: non-targeting interactions mir-9 (includes others)
63.
PMP22
protein-protein interactions LMNA
64.
PRPH
protein-protein interactions MYC
65.
PRPH
protein-protein interactions MYCN
66.
PRPH
protein-protein interactions PDLIM3
67.
RANBP2
protein-protein interactions MYC
68.
RANBP2
protein-protein interactions PDLIM3
69.
REST
protein-DNA interactions mir-9 (includes others)
70.
REST
protein-protein interactions FHL1
71.
SQSTM1
activation AR
72.
SQSTM1
localization AR
73.
SQSTM1
molecular cleavage TARDBP
74.
SQSTM1
protein-protein interactions AR
75.
SQSTM1
protein-protein interactions FUS
76.
SQSTM1
protein-protein interactions MYC
77.
SQSTM1
protein-protein interactions PDLIM3
78.
SQSTM1
protein-protein interactions REST
79.
SQSTM1
protein-protein interactions TARDBP
80.
TARDBP
expression mir-9 (includes others)
81.
TARDBP
protein-protein interactions AGR2
82.
TARDBP
protein-protein interactions CUL3
83.
TARDBP
protein-protein interactions NAA40
84.
TARDBP
protein-protein interactions SQSTM1
85.
VIM
protein-protein interactions AGO2
86.
VIM
protein-protein interactions FUS
87.
VIM
protein-protein interactions FXR1
88.
VIM
protein-protein interactions MYC
89.
VIM
protein-protein interactions MYCN
90.
VIM
protein-protein interactions PDLIM3
91.
YAP1
protein-protein interactions BAG3
92.
YAP1
protein-protein interactions LMNA
93.
YAP1
protein-protein interactions PCNA
94.
YAP1
protein-protein interactions PRPH
95.
YAP1
protein-protein interactions VIM
96.
YAP1
transcription mir-9 (includes others)
97.
mir-9 (includes others)
RNA-RNA interactions: non-targeting interactions AR
98.
mir-9 (includes others)
protein-RNA interactions AGO2
99.
mir-9 (includes others)
protein-RNA interactions AGO3
100.
mir-9 (includes others)
protein-RNA interactions FUS
101.
mir-9 (includes others)
protein-RNA interactions FXR1
Table 11. Various molecules incorporated in the regulation of PDLIM-3 and affect miRNA10 expression.
Table 11. Various molecules incorporated in the regulation of PDLIM-3 and affect miRNA10 expression.
Symbol Entrez Gene Name Location Family
  • ACTN2
actinin alpha 2 Nucleus transcription regulator
2.
AGO1
argonaute RISC component 1 Cytoplasm translation regulator
3.
AGO2
argonaute RISC catalytic component 2 Cytoplasm translation regulator
4.
AGO3
argonaute RISC catalytic component 3 Cytoplasm translation regulator
5.
AGR2
anterior gradient 2, protein disulphide isomerase family member Extracellular Space other
6.
APC
APC regulator of WNT signaling pathway Nucleus enzyme
7.
AR
androgen receptor Nucleus ligand-dependent nuclear receptor
8.
BAG3
BAG cochaperone 3 Cytoplasm other
9.
BICD1
BICD cargo adaptor 1 Cytoplasm other
10.
BTRC
beta-transducin repeat containing E3 ubiquitin protein ligase Cytoplasm enzyme
11.
CD274
CD274 molecule Plasma Membrane transmembrane receptor
12.
CTNNB1
catenin beta 1 Nucleus transcription regulator
13.
CUL3
cullin 3 Nucleus enzyme
14.
DCTN1
dynactin subunit 1 Cytoplasm other
15.
DDX17
DEAD-box helicase 17 Nucleus enzyme
16.
DROSHA
drosha ribonuclease III Nucleus enzyme
17.
E2F3
E2F transcription factor 3 Nucleus transcription regulator
18.
EZH2
enhancer of zeste 2 polycomb repressive complex 2 subunit Nucleus transcription regulator
19.
FHL1
four and a half LIM domains 1 Cytoplasm other
20.
FUS
FUS RNA binding protein Nucleus transcription regulator
21.
JUN
Jun proto-oncogene, AP-1 transcription factor subunit Nucleus transcription regulator
22.
KLC2
kinesin light chain 2 Cytoplasm other
23.
LMNA
lamin A/C Nucleus other
24.
MAP3K7
mitogen-activated protein kinase kinase kinase 7 Cytoplasm kinase
25.
mir-10
relatives of microRNA 10 Cytoplasm microRNA
26.
MYC
MYC proto-oncogene, bHLH transcription factor Nucleus transcription regulator
27.
NAA40
N-alpha-acetyltransferase 40, NatD catalytic subunit Cytoplasm enzyme
28.
NPM1
nucleophosmin 1 Nucleus transcription regulator
29.
PALLD
palladin, cytoskeletal associated protein Plasma Membrane other
30.
PCNA
proliferating cell nuclear antigen Nucleus enzyme
31.
PDLIM3
PDZ and LIM domain 3 Cytoplasm other
32.
PPARA
peroxisome proliferator activated receptor alpha Nucleus ligand-dependent nuclear receptor
33.
PRPH
peripherin Plasma Membrane other
34.
RANBP2
RAN binding protein 2 Nucleus enzyme
35.
RELA
RELA proto-oncogene, NF-kB subunit Nucleus transcription regulator
36.
RHOU
ras homolog family member U Cytoplasm enzyme
37.
RNF207
ring finger protein 207 Other other
38.
SNAI1
snail family transcriptional repressor 1 Nucleus transcription regulator
39.
SQSTM1
sequestosome 1 Cytoplasm transcription regulator
40.
SUV39H1
SUV39H1 histone lysine methyltransferase Nucleus enzyme
41.
TP53
tumor protein p53 Nucleus transcription regulator
42.
TRIM28
tripartite motif containing 28 Nucleus transcription regulator
43.
TWIST1
twist family bHLH transcription factor 1 Nucleus transcription regulator
44.
VIM
vimentin Cytoplasm other
45.
YAP1
Yes1 associated transcriptional regulator Nucleus transcription regulator
Table 12. Various interactions between molecules incorporated in the PDLIM-3 and affect miRNA10 expression.
Table 12. Various interactions between molecules incorporated in the PDLIM-3 and affect miRNA10 expression.
From Molecule(s) Relationship Type To Molecule(s)
  • ACTN2
activation AR
2.
ACTN2
protein-protein interactions AR
3.
AGR2
inhibition TP53
4.
AGR2
protein-protein interactions AGO2
5.
AGR2
protein-protein interactions TP53
6.
AR
expression mir-10
7.
AR
protein-DNA interactions mir-10
8.
AR
protein-protein interactions ACTN2
9.
BICD1
protein-protein interactions AGO1
10.
BICD1
protein-protein interactions AGO3
11.
BTRC
protein-protein interactions BICD1
12.
CD274
expression mir-10
13.
CTNNB1
expression mir-10
14.
CUL3
protein-protein interactions AGO1
15.
CUL3
protein-protein interactions AGO2
16.
CUL3
protein-protein interactions AGO3
17.
CUL3
protein-protein interactions CD274
18.
CUL3
protein-protein interactions CTNNB1
19.
DCTN1
protein-protein interactions APC
20.
DDX17
protein-protein interactions AGR2
21.
DDX17
protein-protein interactions CUL3
22.
DROSHA
protein-DNA interactions mir-10
23.
DROSHA
protein-protein interactions CUL3
24.
E2F3
expression mir-10
25.
EZH2
expression mir-10
26.
EZH2
protein-protein interactions BAG3
27.
EZH2
protein-protein interactions CUL3
28.
EZH2
protein-protein interactions DCTN1
29.
FHL1
protein-protein interactions CTNNB1
30.
FUS
protein-protein interactions AGR2
31.
FUS
protein-protein interactions CUL3
32.
LMNA
activation TP53
33.
LMNA
protein-DNA interactions PPARA
34.
LMNA
protein-protein interactions CTNNB1
35.
LMNA
protein-protein interactions EZH2
36.
LMNA
protein-protein interactions FUS
37.
LMNA
protein-protein interactions TP53
38.
MYC
expression mir-10 (includes others)
39.
MYC
protein-protein interactions BAG3
40.
MYC
protein-protein interactions DCTN1
41.
MYC
protein-protein interactions LMNA
42.
NAA40
protein-protein interactions DDX17
43.
NAA40
protein-protein interactions KLC2
44.
NPM1
expression mir-10 (includes others)
45.
NPM1
protein-protein interactions AGR2
46.
NPM1
protein-protein interactions BICD1
47.
NPM1
protein-protein interactions CUL3
48.
NPM1
protein-protein interactions LMNA
49.
NPM1
protein-protein interactions NAA40
50.
PALLD
protein-protein interactions BTRC
51.
PALLD
protein-protein interactions MYC
52.
PCNA
protein-protein interactions APC
53.
PCNA
protein-protein interactions AR
54.
PCNA
protein-protein interactions CTNNB1
55.
PCNA
protein-protein interactions DDX17
56.
PCNA
protein-protein interactions E2F3
57.
PCNA
protein-protein interactions EZH2
58.
PCNA
protein-protein interactions FUS
59.
PCNA
protein-protein interactions MAP3K7
60.
PCNA
protein-protein interactions MYC
61.
PDLIM3
protein-protein interactions ACTN2
62.
PDLIM3
protein-protein interactions AGR2
63.
PDLIM3
protein-protein interactions BAG3
64.
PDLIM3
protein-protein interactions BICD1
65.
PDLIM3
protein-protein interactions CUL3
66.
PDLIM3
protein-protein interactions DCTN1
67.
PDLIM3
protein-protein interactions FHL1
68.
PDLIM3
protein-protein interactions LMNA
69.
PDLIM3
protein-protein interactions NAA40
70.
PDLIM3
protein-protein interactions PALLD
71.
PDLIM3
protein-protein interactions PCNA
72.
PDLIM3
protein-protein interactions PDLIM3
73.
PPARA
expression mir-10
74.
PRPH
protein-protein interactions MYC
75.
PRPH
protein-protein interactions PDLIM3
76.
RANBP2
protein-protein interactions APC
77.
RANBP2
protein-protein interactions CTNNB1
78.
RANBP2
protein-protein interactions EZH2
79.
RANBP2
protein-protein interactions MYC
80.
RANBP2
protein-protein interactions PDLIM3
81.
RELA
expression mir-10 (includes others)
82.
RELA
protein-DNA interactions mir-10 (includes others)
83.
RELA
protein-protein interactions PCNA
84.
RHOU
protein-protein interactions CTNNB1
85.
RHOU
protein-protein interactions PDLIM3
86.
RNF207
protein-protein interactions NPM1
87.
RNF207
protein-protein interactions PDLIM3
88.
SNAI1
expression mir-10 (includes others)
89.
SNAI1
protein-protein interactions ACTN2
90.
SNAI1
protein-protein interactions PCNA
91.
SNAI1
transcription mir-10 (includes others)
92.
SQSTM1
activation AR
93.
SQSTM1
activation TP53
94.
SQSTM1
expression RELA
95.
SQSTM1
expression SNAI1
96.
SQSTM1
protein-protein interactions AR
97.
SQSTM1
protein-protein interactions CTNNB1
98.
SQSTM1
protein-protein interactions FUS
99.
SQSTM1
protein-protein interactions JUN
100.
SQSTM1
protein-protein interactions MAP3K7
101.
SQSTM1
protein-protein interactions MYC
102.
SQSTM1
protein-protein interactions NPM1
103.
SQSTM1
protein-protein interactions PDLIM3
104.
SQSTM1
protein-protein interactions RELA
105.
SQSTM1
protein-protein interactions SNAI1
106.
SQSTM1
protein-protein interactions TP53
107.
SQSTM1
transcription JUN
108.
SUV39H1
protein-protein interactions PCNA
109.
SUV39H1
protein-protein interactions mir-10
110.
TP53
expression mir-10
111.
TP53
protein-protein interactions AGR2
112.
TP53
protein-protein interactions BICD1
113.
TP53
protein-protein interactions CUL3
114.
TP53
protein-protein interactions LMNA
115.
TP53
protein-protein interactions NAA40
116.
TP53
protein-protein interactions PALLD
117.
TP53
protein-protein interactions PCNA
118.
TP53
protein-protein interactions RANBP2
119.
TP53
protein-protein interactions SQSTM1
120.
TRIM28
expression mir-10
121.
TRIM28
protein-protein interactions AGR2
122.
TRIM28
protein-protein interactions CUL3
123.
TRIM28
protein-protein interactions DCTN1
124.
TRIM28
protein-protein interactions LMNA
125.
TRIM28
protein-protein interactions NAA40
126.
TRIM28
protein-protein interactions PCNA
127.
TRIM28
protein-protein interactions RANBP2
128.
TWIST1
expression mir-10
129.
TWIST1
protein-protein interactions PALLD
130.
VIM
protein-protein interactions AGO1
131.
VIM
protein-protein interactions AGO2
132.
VIM
protein-protein interactions APC
133.
VIM
protein-protein interactions BTRC
134.
VIM
protein-protein interactions EZH2
135.
VIM
protein-protein interactions FUS
136.
VIM
protein-protein interactions MYC
137.
VIM
protein-protein interactions NPM1
138.
VIM
protein-protein interactions PDLIM3
139.
VIM
protein-protein interactions RELA
140.
VIM
protein-protein interactions TP53
141.
VIM
protein-protein interactions TRIM28
142.
YAP1
protein-protein interactions BAG3
143.
YAP1
protein-protein interactions LMNA
144.
YAP1
protein-protein interactions PCNA
145.
YAP1
protein-protein interactions PRPH
146.
YAP1
protein-protein interactions VIM
147.
YAP1
transcription mir-10
148.
mir-10
RNA-RNA interactions: non-targeting interactions APC
149.
mir-10
RNA-RNA interactions: non-targeting interactions BTRC
150.
mir-10
RNA-RNA interactions: non-targeting interactions JUN
151.
mir-10
RNA-RNA interactions: non-targeting interactions MAP3K7
152.
mir-10
protein-RNA interactions AGO1
153.
mir-10
protein-RNA interactions AGO2
154.
mir-10
protein-RNA interactions AGO3
155.
mir-10
protein-RNA interactions DDX17
156.
mir-10
protein-RNA interactions FUS
157.
mir-10
protein-protein interactions KLC2
Table 13. Molecules regulated by Estrogen, PDLIM-3, miRNA9 and miRNA10 affecting RUNX-2 expression.
Table 13. Molecules regulated by Estrogen, PDLIM-3, miRNA9 and miRNA10 affecting RUNX-2 expression.
Symbol Gene Name Location Family
  • ACTN2
actinin alpha 2 Nucleus transcription regulator
2.
AGR2
anterior gradient 2, protein disulphide isomerase family member Extracellular Space other
3.
APC
APC regulator of WNT signaling pathway Nucleus enzyme
4.
AR
androgen receptor Nucleus ligand-dependent nuclear receptor
5.
BAG3
BAG cochaperone 3 Cytoplasm Other
6.
CTNNB1
catenin beta 1 Nucleus transcription regulator
7.
CUL3
cullin 3 Nucleus Enzyme
8.
DCTN1
dynactin subunit 1 Cytoplasm Other
9.
EGF
epidermal growth factor Extracellular Space growth factor
10.
ERBB2
erb-b2 receptor tyrosine kinase 2 Plasma Membrane Kinase
11.
ESR1
estrogen receptor 1 Nucleus ligand-dependent nuclear receptor
12.
ESR2
estrogen receptor 2 Nucleus ligand-dependent nuclear receptor
13.
ETS1
ETS proto-oncogene 1, transcription factor Nucleus transcription regulator
14.
EZH2
enhancer of zeste 2 polycomb repressive complex 2 subunit Nucleus transcription regulator
15.
FHL1
four and a half LIM domains 1 Cytoplasm other
16.
FKBP4
FKBP prolyl isomerase 4 Nucleus enzyme
17.
HDAC4
histone deacetylase 4 Nucleus transcription regulator
18.
HSP90 (family)
Cytoplasm group
19.
JUN
Jun proto-oncogene, AP-1 transcription factor subunit Nucleus transcription regulator
20.
KLF4
KLF transcription factor 4 Nucleus transcription regulator
21.
LMNA
lamin A/C Nucleus other
22.
mir-10
relatives of microRNA 10 Cytoplasm microRNA
23.
mir-9
relatives of microRNA 9 Cytoplasm microRNA
24.
MYC
MYC proto-oncogene, bHLH transcription factor Nucleus transcription regulator
25.
NAA40
N-alpha-acetyltransferase 40, NatD catalytic subunit Cytoplasm enzyme
26.
NPM1
nucleophosmin 1 Nucleus transcription regulator
27.
PALLD
palladin, cytoskeletal associated protein Plasma Membrane other
28.
PCNA
proliferating cell nuclear antigen Nucleus enzyme
29.
PDLIM3
PDZ and LIM domain 3 Cytoplasm other
30.
PRPH
peripherin Plasma Membrane other
31.
RANBP2
RAN binding protein 2 Nucleus enzyme
32.
RUNX1
RUNX family transcription factor 1 Nucleus transcription regulator
33.
RUNX2
RUNX family transcription factor 2 Nucleus transcription regulator
34.
RYR1
ryanodine receptor 1 Cytoplasm ion channel
35.
SMAD2
SMAD family member 2 Nucleus transcription regulator
36.
SMAD4
SMAD family member 4 Nucleus transcription regulator
37.
SNAI1
snail family transcriptional repressor 1 Nucleus transcription regulator
38.
SQSTM1
sequestosome 1 Cytoplasm transcription regulator
39.
SUV39H1
SUV39H1 histone lysine methyltransferase Nucleus enzyme
40.
TP53
tumor protein p53 Nucleus transcription regulator
41.
VIM
vimentin Cytoplasm other
Table 14. Various interactions regulated by Estrogen, PDLIM-3, miRNA9 and miRNA10 affecting RUNX-2.
Table 14. Various interactions regulated by Estrogen, PDLIM-3, miRNA9 and miRNA10 affecting RUNX-2.
From Molecule(s) Relationship Type To Molecule(s)
  • AR
expression mir-10 (includes others)
2.
AR
protein-DNA interactions mir-10 (includes others)
3.
ERBB2
protein-protein interactions CUL3
4.
ESR1
activation RUNX2
5.
ESR1
chemical-protein interactions estrogen
6.
ESR1
expression RUNX2
7.
ESR1
inhibition RUNX2
8.
ESR1
protein-protein interactions CUL3
9.
ESR1
protein-protein interactions RUNX2
10.
ESR1
transcription RUNX2
11.
ESR2
chemical-protein interactions estrogen
12.
ESR2
expression RUNX2
13.
ESR2
protein-protein interactions CUL3
14.
ESR2
protein-protein interactions DCTN1
15.
ETS1
protein-DNA interactions RUNX2
16.
ETS1
protein-protein interactions RUNX2
17.
ETS1
transcription RUNX2
18.
EZH2
expression mir-10 (includes others)
19.
FHL1
protein-protein interactions ESR1
20.
FKBP4
chemical-protein interactions estrogen
21.
FKBP4
protein-protein interactions AGR2
22.
HDAC4
activation RUNX2
23.
HDAC4
expression RUNX2
24.
HDAC4
protein-protein interactions RUNX2
25.
HSP90 (family)
chemical-protein interactions estrogen
26.
HSP90 (family)
protein-protein interactions CUL3
27.
JUN
protein-DNA interactions RUNX2
28.
JUN
protein-protein interactions RUNX2
29.
KLF4
expression RUNX2
30.
KLF4
protein-DNA interactions RUNX2
31.
KLF4
protein-protein interactions RUNX2
32.
LMNA
protein-protein interactions CTNNB1
33.
LMNA
protein-protein interactions EGF
34.
LMNA
protein-protein interactions ESR1
35.
LMNA
protein-protein interactions HSP90 (family)
36.
MYC
expression mir-9 (includes others)
37.
MYC
protein-DNA interactions mir-9 (includes others)
38.
MYC
protein-protein interactions BAG3
39.
MYC
protein-protein interactions DCTN1
40.
MYC
protein-protein interactions LMNA
41.
MYC
transcription mir-9 (includes others)
42.
NAA40
protein-protein interactions FKBP4
43.
NPM1
expression mir-10 (includes others)
44.
NPM1
protein-protein interactions LMNA
45.
PALLD
protein-protein interactions MYC
46.
PCNA
protein-protein interactions ESR2
47.
PCNA
protein-protein interactions EZH2
48.
PCNA
protein-protein interactions MYC
49.
PDLIM3
protein-protein interactions ACTN2
50.
PDLIM3
protein-protein interactions AGR2
51.
PDLIM3
protein-protein interactions BAG3
52.
PDLIM3
protein-protein interactions CUL3
53.
PDLIM3
protein-protein interactions DCTN1
54.
PDLIM3
protein-protein interactions FHL1
55.
PDLIM3
protein-protein interactions LMNA
56.
PDLIM3
protein-protein interactions NAA40
57.
PDLIM3
protein-protein interactions PALLD
58.
PDLIM3
protein-protein interactions PCNA
59.
PDLIM3
protein-protein interactions PDLIM3
60.
PRPH
protein-protein interactions MYC
61.
PRPH
protein-protein interactions PDLIM3
62.
RANBP2
protein-protein interactions APC
63.
RANBP2
protein-protein interactions ERBB2
64.
RANBP2
protein-protein interactions ESR1
65.
RANBP2
protein-protein interactions ESR2
66.
RANBP2
protein-protein interactions PDLIM3
67.
RUNX1
expression RUNX2
68.
RUNX1
protein-DNA interactions RUNX2
69.
RUNX1
protein-protein interactions RUNX2
70.
RUNX2
activation RUNX2
71.
RUNX2
expression RUNX2
72.
RUNX2
inhibition RUNX2
73.
RUNX2
localization RUNX2
74.
RUNX2
modification RUNX2
75.
RUNX2
molecular cleavage RUNX2
76.
RUNX2
protein-DNA interactions RUNX2
77.
RUNX2
protein-protein interactions AR
78.
RUNX2
protein-protein interactions BAG3
79.
RUNX2
protein-protein interactions ESR1
80.
RUNX2
protein-protein interactions ETS1
81.
RUNX2
protein-protein interactions HDAC4
82.
RUNX2
protein-protein interactions JUN
83.
RUNX2
protein-protein interactions KLF4
84.
RUNX2
protein-protein interactions RUNX1
85.
RUNX2
protein-protein interactions SMAD4
86.
RUNX2
regulation of binding RUNX2
87.
RUNX2
ubiquitination RUNX2
88.
RYR1
protein-protein interactions ESR2
89.
RYR1
protein-protein interactions PDLIM3
90.
SMAD2
expression RUNX2
91.
SMAD2
protein-protein interactions RUNX2
92.
SMAD4
expression RUNX2
93.
SMAD4
protein-DNA interactions RUNX2
94.
SMAD4
protein-protein interactions RUNX2
95.
SNAI1
expression mir-10 (includes others)
96.
SNAI1
protein-protein interactions ACTN2
97.
SNAI1
transcription mir-10 (includes others)
98.
SQSTM1
protein-protein interactions CTNNB1
99.
SQSTM1
protein-protein interactions ESR1
100.
SQSTM1
protein-protein interactions ESR2
101.
SQSTM1
protein-protein interactions FKBP4
102.
SQSTM1
protein-protein interactions NPM1
103.
SQSTM1
protein-protein interactions PDLIM3
104.
SUV39H1
protein-protein interactions RUNX2
105.
SUV39H1
protein-protein interactions mir-10 (includes others)
106.
TP53
expression RUNX2
107.
TP53
protein-protein interactions RUNX2
108.
TP53
transcription RUNX2
109.
VIM
protein-protein interactions ESR2
110.
VIM
protein-protein interactions MYC
111.
VIM
protein-protein interactions PDLIM3
112.
estrogen
activation ESR1
113.
estrogen
activation ESR2
114.
estrogen
activation RUNX2
115.
estrogen
chemical-protein interactions EGF
116.
estrogen
chemical-protein interactions ERBB2
117.
estrogen
chemical-protein interactions ESR1
118.
estrogen
chemical-protein interactions ESR2
119.
estrogen
translocation estrogen
120.
mir-10 (includes others)
RNA-RNA interactions: microRNA targeting AR
121.
mir-10 (includes others)
RNA-RNA interactions: microRNA targeting HDAC4
122.
mir-10 (includes others)
RNA-RNA interactions: microRNA targeting KLF4
123.
mir-10 (includes others)
RNA-RNA interactions: microRNA targeting SMAD2
124.
mir-10 (includes others)
RNA-RNA interactions: microRNA targeting SMAD4
125.
mir-10 (includes others)
RNA-RNA interactions: microRNA targeting SUV39H1
126.
mir-10 (includes others)
RNA-RNA interactions: non-targeting interactions APC
127.
mir-10 (includes others)
RNA-RNA interactions: non-targeting interactions JUN
128.
mir-10 (includes others)
expression AR
129.
mir-10 (includes others)
protein-protein interactions SUV39H1
130.
mir-9 (includes others)
RNA-RNA interactions: microRNA targeting AR
131.
mir-9 (includes others)
RNA-RNA interactions: microRNA targeting ETS1
132.
mir-9 (includes others)
RNA-RNA interactions: microRNA targeting RUNX1
133.
mir-9 (includes others)
RNA-RNA interactions: non-targeting interactions AR
134.
mir-9 (includes others)
expression AR
135.
mir-9 (includes others)
expression ETS1
136.
mir-9 (includes others)
expression RUNX1
Table 15. Molecules regulated by Estrogen, PDLIM-3, , microRNA-1896, microRNA6769B, affecting RUNX-2.
Table 15. Molecules regulated by Estrogen, PDLIM-3, , microRNA-1896, microRNA6769B, affecting RUNX-2.
Symbol Molecule/ Gene Name Location Family
  • AR
androgen receptor Nucleus ligand-dependent nuclear receptor
2.
CBX5
chromobox 5 Nucleus transcription regulator
3.
CCND1
cyclin D1 Nucleus transcription regulator
4.
CDK4
cyclin dependent kinase 4 Nucleus kinase
5.
CUL3
cullin 3 Nucleus Enzyme
6.
DCTN1
dynactin subunit 1 Cytoplasm Other
7.
ELF4
E74 like ETS transcription factor 4 Nucleus transcription regulator
8.
ESR1
estrogen receptor 1 Nucleus ligand-dependent nuclear receptor
9.
ESR2
estrogen receptor 2 Nucleus ligand-dependent nuclear receptor
10.
estrogen
Other chemical drug
11.
FOSB
FosB proto-oncogene, AP-1 transcription factor subunit Nucleus transcription regulator
12.
FOSL1
FOS like 1, AP-1 transcription factor subunit Nucleus transcription regulator
13.
FOSL2
FOS like 2, AP-1 transcription factor subunit Nucleus transcription regulator
14.
FSH
Plasma Membrane Complex
15.
HDAC7
histone deacetylase 7 Nucleus transcription regulator
16.
HES1
hes family bHLH transcription factor 1 Nucleus transcription regulator
17.
HIVEP3
HIVEP zinc finger 3 Nucleus transcription regulator
18.
HOXA11
homeobox A11 Nucleus transcription regulator
19.
LH
Plasma Membrane Complex
20.
LMNA
lamin A/C Nucleus Other
21.
MAPK1
mitogen-activated protein kinase 1 Cytoplasm Kinase
22.
MEIS2
Meis homeobox 2 Nucleus transcription regulator
23.
METTL14
methyltransferase 14, N6-adenosine-methyltransferase subunit Nucleus Enzyme
24.
miR-1896
Cytoplasm mature microRNA
25.
MIR6769B
microRNA 6769b Other microRNA
26.
NAA40
N-alpha-acetyltransferase 40, NatD catalytic subunit Cytoplasm Enzyme
27.
NFIA
nuclear factor I A Nucleus transcription regulator
28.
PBX3
PBX homeobox 3 Nucleus transcription regulator
29.
PCNA
proliferating cell nuclear antigen Nucleus Enzyme
30.
PDLIM3
PDZ and LIM domain 3 Cytoplasm Other
31.
PPARD
peroxisome proliferator activated receptor delta Nucleus ligand-dependent nuclear receptor
32.
PPARGC1B
PPARG coactivator 1 beta Nucleus transcription regulator
33.
RUNX2
RUNX family transcription factor 2 Nucleus transcription regulator
34.
SUV39H1
SUV39H1 histone lysine methyltransferase Nucleus Enzyme
35.
TAFAZZIN
tafazzin, phospholipid-lysophospholipid transacylase Nucleus Enzyme
36.
TET3
tet methylcytosine dioxygenase 3 Nucleus Enzyme
37.
THRAP3
thyroid hormone receptor associated protein 3 Nucleus transcription regulator
38.
TSC22D3
TSC22 domain family member 3 Nucleus transcription regulator
39.
TWIST2
twist family bHLH transcription factor 2 Nucleus transcription regulator
40.
UBTF
upstream binding transcription factor Nucleus transcription regulator
41.
VDR
vitamin D receptor Nucleus transcription regulator
42.
VIM
vimentin Cytoplasm Other
43.
YTHDF2
YTH N6-methyladenosine RNA binding protein F2 Cytoplasm Other
Table 16. Various interactions regulated by estrogen, PDLIM-3. microRNA-1896, microRNA6769B affecting RUNX-2.
Table 16. Various interactions regulated by estrogen, PDLIM-3. microRNA-1896, microRNA6769B affecting RUNX-2.
From Molecule(s) Relationship Type To Molecule(s)
  • CBX5
expression RUNX2
2.
CCND1
expression PDLIM3
3.
CDK4
expression PDLIM3
4.
ESR1
chemical-protein interactions estrogen
5.
ESR1
expression PDLIM3
6.
ESR1
regulation of binding estrogen
7.
ESR2
chemical-protein interactions estrogen
8.
ESR2
expression PDLIM3
9.
FOSB
protein-DNA interactions RUNX2
10.
FOSL1
protein-DNA interactions RUNX2
11.
FOSL2
protein-DNA interactions RUNX2
12.
FSH
expression PDLIM3
13.
HES1
activation RUNX2
14.
HES1
protein-protein interactions RUNX2
15.
HIVEP3
inhibition RUNX2
16.
HIVEP3
protein-protein interactions RUNX2
17.
HOXA11
expression RUNX2
18.
HOXA11
protein-protein interactions RUNX2
19.
HOXA11
transcription RUNX2
20.
LH
expression PDLIM3
21.
LMNA
protein-DNA interactions YTHDF2
22.
MAPK1
expression PDLIM3
23.
MEIS2
expression RUNX2
24.
METTL14
expression MIR6769B
25.
METTL14
protein-protein interactions LMNA
26.
MIR6769B
processing yields miR-1896
27.
NFIA
expression RUNX2
28.
PBX3
expression RUNX2
29.
PDLIM3
protein-protein interactions CUL3
30.
PDLIM3
protein-protein interactions DCTN1
31.
PDLIM3
protein-protein interactions LMNA
32.
PDLIM3
protein-protein interactions NAA40
33.
PDLIM3
protein-protein interactions PCNA
34.
PPARD
expression RUNX2
35.
PPARGC1B
transcription RUNX2
36.
RUNX2
activation RUNX2
37.
RUNX2
expression RUNX2
38.
RUNX2
inhibition HIVEP3
39.
RUNX2
inhibition RUNX2
40.
RUNX2
localization RUNX2
41.
RUNX2
modification RUNX2
42.
RUNX2
molecular cleavage RUNX2
43.
RUNX2
protein-DNA interactions RUNX2
44.
RUNX2
protein-protein interactions AR
45.
RUNX2
protein-protein interactions ELF4
46.
RUNX2
protein-protein interactions HDAC7
47.
RUNX2
protein-protein interactions HES1
48.
RUNX2
protein-protein interactions HIVEP3
49.
RUNX2
protein-protein interactions HOXA11
50.
RUNX2
protein-protein interactions TAFAZZIN
51.
RUNX2
regulation of binding RUNX2
52.
RUNX2
ubiquitination RUNX2
53.
SUV39H1
protein-protein interactions RUNX2
54.
TAFAZZIN
protein-protein interactions RUNX2
55.
TET3
protein-protein interactions RUNX2
56.
THRAP3
expression RUNX2
57.
TSC22D3
expression RUNX2
58.
TWIST2
protein-protein interactions RUNX2
59.
UBTF
protein-protein interactions RUNX2
60.
VDR
expression RUNX2
61.
VDR
protein-protein interactions RUNX2
62.
VIM
protein-protein interactions METTL14
63.
VIM
protein-protein interactions PDLIM3
64.
YTHDF2
expression MIR6769B
65.
YTHDF2
protein-protein interactions CUL3
66.
YTHDF2
protein-protein interactions DCTN1
67.
YTHDF2
protein-protein interactions NAA40
68.
estrogen
activation CDK4
69.
estrogen
activation ESR1
70.
estrogen
activation ESR2
71.
estrogen
activation MAPK1
72.
estrogen
chemical-protein interactions ESR1
73.
estrogen
chemical-protein interactions ESR2
74.
estrogen
expression CCND1
75.
estrogen
expression ESR1
76.
estrogen
expression ESR2
77.
estrogen
expression FSH
78.
estrogen
expression LH
79.
estrogen
expression PCNA
80.
estrogen
localization FSH
81.
estrogen
localization LH
82.
estrogen
molecular cleavage ESR1
83.
estrogen
phosphorylation ESR1
84.
estrogen
phosphorylation ESR2
85.
estrogen
phosphorylation MAPK1
86.
estrogen
regulation of binding CCND1
87.
estrogen
regulation of binding CDK4
88.
estrogen
regulation of binding ESR1
89.
estrogen
regulation of binding ESR2
90.
estrogen
transcription CCND1
91.
estrogen
translocation ESR1
92.
estrogen
translocation ESR2
93.
miR-1896
RNA-RNA interactions: microRNA targeting AR
94.
miR-1896
RNA-RNA interactions: microRNA targeting CBX5
95.
miR-1896
RNA-RNA interactions: microRNA targeting ELF4
96.
miR-1896
RNA-RNA interactions: microRNA targeting FOSB
97.
miR-1896
RNA-RNA interactions: microRNA targeting FOSL1
98.
miR-1896
RNA-RNA interactions: microRNA targeting FOSL2
99.
miR-1896
RNA-RNA interactions: microRNA targeting HDAC7
100.
miR-1896
RNA-RNA interactions: microRNA targeting HES1
101.
miR-1896
RNA-RNA interactions: microRNA targeting HIVEP3
102.
miR-1896
RNA-RNA interactions: microRNA targeting HOXA11
103.
miR-1896
RNA-RNA interactions: microRNA targeting MEIS2
104.
miR-1896
RNA-RNA interactions: microRNA targeting NFIA
105.
miR-1896
RNA-RNA interactions: microRNA targeting PBX3
106.
miR-1896
RNA-RNA interactions: microRNA targeting PPARD
107.
miR-1896
RNA-RNA interactions: microRNA targeting PPARGC1B
108.
miR-1896
RNA-RNA interactions: microRNA targeting RUNX2
109.
miR-1896
RNA-RNA interactions: microRNA targeting SUV39H1
110.
miR-1896
RNA-RNA interactions: microRNA targeting TAFAZZIN
111.
miR-1896
RNA-RNA interactions: microRNA targeting TET3
112.
miR-1896
RNA-RNA interactions: microRNA targeting THRAP3
113.
miR-1896
RNA-RNA interactions: microRNA targeting TSC22D3
114.
miR-1896
RNA-RNA interactions: microRNA targeting TWIST2
115.
miR-1896
RNA-RNA interactions: microRNA targeting UBTF
116.
miR-1896
RNA-RNA interactions: microRNA targeting VDR
117.
miR-1896
expression RUNX2
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

Subscribe

Disclaimer

Terms of Use

Privacy Policy

Privacy Settings

© 2025 MDPI (Basel, Switzerland) unless otherwise stated